1
|
Aoki H, Takasawa A, Yamamoto E, Niinuma T, Yamano HO, Harada T, Kubo T, Yorozu A, Kitajima H, Ishiguro K, Kai M, Katanuma A, Shinohara T, Nakase H, Sugai T, Osanai M, Suzuki H. Downregulation of SMOC1 is associated with progression of colorectal traditional serrated adenomas. BMC Gastroenterol 2024; 24:91. [PMID: 38429655 PMCID: PMC10905814 DOI: 10.1186/s12876-024-03175-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/20/2023] [Accepted: 02/15/2024] [Indexed: 03/03/2024] Open
Abstract
BACKGROUND Aberrant DNA methylation is prevalent in colorectal serrated lesions. We previously reported that the CpG island of SMOC1 is frequently methylated in traditional serrated adenomas (TSAs) and colorectal cancers (CRCs) but is rarely methylated in sessile serrated lesions (SSLs). In the present study, we aimed to further characterize the expression of SMOC1 in early colorectal lesions. METHODS SMOC1 expression was analyzed immunohistochemically in a series of colorectal tumors (n = 199) and adjacent normal colonic tissues (n = 112). RESULTS SMOC1 was abundantly expressed in normal colon and SSLs while it was significantly downregulated in TSAs, advanced adenomas and cancers. Mean immunohistochemistry scores were as follows: normal colon, 24.2; hyperplastic polyp (HP), 18.9; SSL, 23.8; SSL with dysplasia (SSLD)/SSL with early invasive cancer (EIC), 15.8; TSA, 5.4; TSA with high grade dysplasia (HGD)/EIC, 4.7; non-advanced adenoma, 21.4; advanced adenoma, 11.9; EIC, 10.9. Higher levels SMOC1 expression correlated positively with proximal colon locations and flat tumoral morphology, reflecting its abundant expression in SSLs. Among TSAs that contained both flat and protruding components, levels of SMOC1 expression were significantly lower in the protruding components. CONCLUSION Our results suggest that reduced expression of SMOC1 is associated with progression of TSAs and conventional adenomas and that SMOC1 expression may be a biomarker for diagnosis of serrated lesions and risk prediction in colorectal tumors.
Collapse
Affiliation(s)
- Hironori Aoki
- Department of Molecular Biology, Sapporo Medical University School of Medicine, S1, W17, Chuo-Ku, Sapporo, 060-8556, Japan
- Center for Gastroenterology, Teine-Keijinkai Hospital, Sapporo, Japan
- Department of Gastroenterology and Endoscopy, Koyukai Shin-Sapporo Hospital, Sapporo, Japan
| | - Akira Takasawa
- Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Eiichiro Yamamoto
- Department of Molecular Biology, Sapporo Medical University School of Medicine, S1, W17, Chuo-Ku, Sapporo, 060-8556, Japan
| | - Takeshi Niinuma
- Department of Molecular Biology, Sapporo Medical University School of Medicine, S1, W17, Chuo-Ku, Sapporo, 060-8556, Japan
| | - Hiro-O Yamano
- Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Taku Harada
- Department of Molecular Biology, Sapporo Medical University School of Medicine, S1, W17, Chuo-Ku, Sapporo, 060-8556, Japan
- Center for Gastroenterology, Teine-Keijinkai Hospital, Sapporo, Japan
| | - Toshiyuki Kubo
- Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Akira Yorozu
- Department of Molecular Biology, Sapporo Medical University School of Medicine, S1, W17, Chuo-Ku, Sapporo, 060-8556, Japan
| | - Hiroshi Kitajima
- Department of Molecular Biology, Sapporo Medical University School of Medicine, S1, W17, Chuo-Ku, Sapporo, 060-8556, Japan
| | - Kazuya Ishiguro
- Department of Molecular Biology, Sapporo Medical University School of Medicine, S1, W17, Chuo-Ku, Sapporo, 060-8556, Japan
| | - Masahiro Kai
- Department of Molecular Biology, Sapporo Medical University School of Medicine, S1, W17, Chuo-Ku, Sapporo, 060-8556, Japan
| | - Akio Katanuma
- Center for Gastroenterology, Teine-Keijinkai Hospital, Sapporo, Japan
| | | | - Hiroshi Nakase
- Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Tamotsu Sugai
- Department of Molecular Diagnostic Pathology, Iwate Medical University, Morioka, Japan
| | - Makoto Osanai
- Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Hiromu Suzuki
- Department of Molecular Biology, Sapporo Medical University School of Medicine, S1, W17, Chuo-Ku, Sapporo, 060-8556, Japan.
| |
Collapse
|
2
|
Kitajima H, Maruyama R, Niinuma T, Yamamoto E, Takasawa A, Takasawa K, Ishiguro K, Tsuyada A, Suzuki R, Sudo G, Kubo T, Mitsuhashi K, Idogawa M, Tange S, Toyota M, Yoshido A, Kumegawa K, Kai M, Yanagihara K, Tokino T, Osanai M, Nakase H, Suzuki H. TM4SF1-AS1 inhibits apoptosis by promoting stress granule formation in cancer cells. Cell Death Dis 2023; 14:424. [PMID: 37443145 PMCID: PMC10345132 DOI: 10.1038/s41419-023-05953-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2022] [Revised: 06/30/2023] [Accepted: 07/05/2023] [Indexed: 07/15/2023]
Abstract
Long noncoding RNAs (lncRNAs) play pivotal roles in tumor development. To identify dysregulated lncRNAs in gastric cancer (GC), we analyzed genome-wide trimethylation of histone H3 lysine 4 (H3K4me3) to screen for transcriptionally active lncRNA genes in the non-tumorous gastric mucosa of patients with GC and healthy individuals. We found that H3K4me3 at TM4SF1-AS1 was specifically upregulated in GC patients and that the expression of TM4SF1-AS1 was significantly elevated in primary and cultured GC cells. TM4SF1-AS1 contributes to GC cell growth in vitro and in vivo, and its oncogenic function is mediated, at least in part, through interactions with purine-rich element-binding protein α (Pur-α) and Y-box binding protein 1 (YB-1). TM4SF1-AS1 also activates interferon signaling in GC cells, which is dependent on Pur-α and RIG-I. Chromatin isolation by RNA purification (ChIRP)-mass spectrometry demonstrated that TM4SF1-AS1 was associated with several stress granule (SG)-related proteins, including G3BP2, RACK1, and DDX3. Notably, TM4SF1-AS1 promoted SG formation and inhibited apoptosis in GC cells by sequestering RACK1, an activator of the stress-responsive MAPK pathway, within SGs. TM4SF1-AS1-induced SG formation and apoptosis inhibition are dependent on Pur-α and YB-1. These findings suggested that TM4SF1-AS1 contributes to tumorigenesis by enhancing SG-mediated stress adaptation.
Collapse
Affiliation(s)
- Hiroshi Kitajima
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Reo Maruyama
- Project for Cancer Epigenomics, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan
- Cancer Cell Diversity Project, NEXT-Ganken Program, Japanese Foundation for Cancer Research, Tokyo, Japan
| | - Takeshi Niinuma
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Eiichiro Yamamoto
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Akira Takasawa
- Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Kumi Takasawa
- Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Kazuya Ishiguro
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Akihiro Tsuyada
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Ryo Suzuki
- Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Gota Sudo
- Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Toshiyuki Kubo
- Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Kei Mitsuhashi
- Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Masashi Idogawa
- Department of Medical Genome Sciences, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Shoichiro Tange
- Department of Medical Genome Sciences, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Mutsumi Toyota
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Ayano Yoshido
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Kohei Kumegawa
- Cancer Cell Diversity Project, NEXT-Ganken Program, Japanese Foundation for Cancer Research, Tokyo, Japan
| | - Masahiro Kai
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Kazuyoshi Yanagihara
- Division of Rare Cancer Research, National Cancer Center Research Institute, Tokyo, Japan
| | - Takashi Tokino
- Department of Medical Genome Sciences, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Makoto Osanai
- Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Hiroshi Nakase
- Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Hiromu Suzuki
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan.
| |
Collapse
|
3
|
de Matos Simoes R, Shirasaki R, Downey-Kopyscinski SL, Matthews GM, Barwick BG, Gupta VA, Dupéré-Richer D, Yamano S, Hu Y, Sheffer M, Dhimolea E, Dashevsky O, Gandolfi S, Ishiguro K, Meyers RM, Bryan JG, Dharia NV, Hengeveld PJ, Brüggenthies JB, Tang H, Aguirre AJ, Sievers QL, Ebert BL, Glassner BJ, Ott CJ, Bradner JE, Kwiatkowski NP, Auclair D, Levy J, Keats JJ, Groen RWJ, Gray NS, Culhane AC, McFarland JM, Dempster JM, Licht JD, Boise LH, Hahn WC, Vazquez F, Tsherniak A, Mitsiades CS. Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias. Nat Cancer 2023; 4:754-773. [PMID: 37237081 PMCID: PMC10918623 DOI: 10.1038/s43018-023-00550-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/16/2021] [Accepted: 03/29/2023] [Indexed: 05/28/2023]
Abstract
Clinical progress in multiple myeloma (MM), an incurable plasma cell (PC) neoplasia, has been driven by therapies that have limited applications beyond MM/PC neoplasias and do not target specific oncogenic mutations in MM. Instead, these agents target pathways critical for PC biology yet largely dispensable for malignant or normal cells of most other lineages. Here we systematically characterized the lineage-preferential molecular dependencies of MM through genome-scale clustered regularly interspaced short palindromic repeats (CRISPR) studies in 19 MM versus hundreds of non-MM lines and identified 116 genes whose disruption more significantly affects MM cell fitness compared with other malignancies. These genes, some known, others not previously linked to MM, encode transcription factors, chromatin modifiers, endoplasmic reticulum components, metabolic regulators or signaling molecules. Most of these genes are not among the top amplified, overexpressed or mutated in MM. Functional genomics approaches thus define new therapeutic targets in MM not readily identifiable by standard genomic, transcriptional or epigenetic profiling analyses.
Collapse
Affiliation(s)
- Ricardo de Matos Simoes
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
- Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA
- Ludwig Center at Harvard, Boston, MA, USA
| | - Ryosuke Shirasaki
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
- Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA
- Ludwig Center at Harvard, Boston, MA, USA
| | - Sondra L Downey-Kopyscinski
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
- Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA
| | - Geoffrey M Matthews
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
- Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA
| | - Benjamin G Barwick
- Department of Hematology and Medical Oncology and the Winship Cancer Institute, Emory University, Atlanta, GA, USA
| | - Vikas A Gupta
- Department of Hematology and Medical Oncology and the Winship Cancer Institute, Emory University, Atlanta, GA, USA
| | | | - Shizuka Yamano
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
| | - Yiguo Hu
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
| | - Michal Sheffer
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
- Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA
- Ludwig Center at Harvard, Boston, MA, USA
| | - Eugen Dhimolea
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
- Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA
- Ludwig Center at Harvard, Boston, MA, USA
| | - Olga Dashevsky
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
- Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA
- Ludwig Center at Harvard, Boston, MA, USA
| | - Sara Gandolfi
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
- Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA
- Ludwig Center at Harvard, Boston, MA, USA
| | - Kazuya Ishiguro
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
| | - Robin M Meyers
- Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA
| | - Jordan G Bryan
- Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA
| | - Neekesh V Dharia
- Harvard Medical School, Boston, MA, USA
- Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA
- Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
| | - Paul J Hengeveld
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
| | - Johanna B Brüggenthies
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
- Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA
| | - Huihui Tang
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
- Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA
- Ludwig Center at Harvard, Boston, MA, USA
| | - Andrew J Aguirre
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
- Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA
| | - Quinlan L Sievers
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
- Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA
| | - Benjamin L Ebert
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
- Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA
| | - Brian J Glassner
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
- Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA
| | - Christopher J Ott
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
- Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA
- Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - James E Bradner
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
- Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA
| | - Nicholas P Kwiatkowski
- Harvard Medical School, Boston, MA, USA
- Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA
| | | | - Joan Levy
- Multiple Myeloma Research Foundation, Norwalk, CT, USA
| | | | - Richard W J Groen
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
- Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands
| | - Nathanael S Gray
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
- Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA
| | - Aedin C Culhane
- Department of Data Sciences, Dana-Farber Cancer Institute & Harvard School of Public Health, Boston, MA, USA
- Limerick Digital Cancer Research Center, Health Research Institute, School of Medicine, University of Limerick, Limerick, Ireland
| | - James M McFarland
- Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA
| | - Joshua M Dempster
- Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA
| | - Jonathan D Licht
- University of Florida Health Cancer Center, Gainesville, FL, USA
| | - Lawrence H Boise
- Department of Hematology and Medical Oncology and the Winship Cancer Institute, Emory University, Atlanta, GA, USA
| | - William C Hahn
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
- Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA
| | - Francisca Vazquez
- Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
| | - Aviad Tsherniak
- Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
| | - Constantine S Mitsiades
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
- Harvard Medical School, Boston, MA, USA.
- Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
- Ludwig Center at Harvard, Boston, MA, USA.
| |
Collapse
|
4
|
Yoshido A, Sudo G, Takasawa A, Aoki H, Kitajima H, Yamamoto E, Niinuma T, Harada T, Kubo T, Sasaki H, Ishiguro K, Yorozu A, Kai M, Katanuma A, Yamano HO, Osanai M, Nakase H, Suzuki H. Serum amyloid A1 recruits neutrophils to the invasive front of T1 colorectal cancers. J Gastroenterol Hepatol 2023; 38:301-310. [PMID: 36345658 DOI: 10.1111/jgh.16055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/07/2022] [Revised: 11/01/2022] [Accepted: 11/04/2022] [Indexed: 11/11/2022]
Abstract
BACKGROUND AND AIM The tumor microenvironment plays an essential role in the development and progression of colorectal cancer (CRC). We recently reported that crosstalk between CRC cells and tumor-associated macrophages (TAMs) via serum amyloid A1 (SAA1) promotes invasion by T1 CRCs. In the present study, we aimed to clarify the role of neutrophils in early CRCs. METHODS Immunohistochemical analysis of CD66b, chemokine CXC motif ligand 8 (CXCL8 or interleukin-8, IL-8) and matrix metalloproteinase-9 (MMP-9) was performed using primary T1 CRCs (n = 49). The HL-60 human promyelocytic leukemia cell line and THP-1 human monocytic leukemia cell line were used to obtain neutrophil-like and macrophage-like cells, respectively. Boyden chamber assays were used to analyze cell migration and invasion, and quantitative RT-PCR was used to analyze gene expression. RESULTS Immunohistochemical analysis revealed accumulation of neutrophils at the SAA1-positive invasive front of T1 CRCs. Experiments using HL-60 cells suggested that treatment with SAA1 induced neutrophil migration and expression of CXCL8 and MMP-9 in neutrophils and that neutrophils promote CRC cell migration and invasion. Immunohistochemistry confirmed accumulation of CXCL8- or MMP-9-positive neutrophils at the SAA1-positive invasive front of T1 CRCs. Moreover, co-culture experiments using CRC, THP-1 and HL-60 cells suggested that CRC cells activated by macrophages upregulate CXCL8 and MMP-9 in neutrophils. CONCLUSIONS Our results suggest that interplay between macrophages and CRC cells leads to recruitment of neutrophils to the invasive front of T1 CRCs and that SAA1 secreted by CRC cells activate neutrophils to promote invasion.
Collapse
Affiliation(s)
- Ayano Yoshido
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Gota Sudo
- Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Akira Takasawa
- Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Hironori Aoki
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Hiroshi Kitajima
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Eiichiro Yamamoto
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Takeshi Niinuma
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Taku Harada
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan.,Center for Gastroenterology, Teine-Keijinkai Hospital, Sapporo, Japan
| | - Toshiyuki Kubo
- Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Hajime Sasaki
- Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Kazuya Ishiguro
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Akira Yorozu
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Masahiro Kai
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Akio Katanuma
- Center for Gastroenterology, Teine-Keijinkai Hospital, Sapporo, Japan
| | - Hiro-O Yamano
- Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Makoto Osanai
- Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Hiroshi Nakase
- Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Hiromu Suzuki
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan
| |
Collapse
|
5
|
Ishiguro K, Sato T, Shichiji M, Kihara Y, Murakami T, Nagata S, Ishigaki K. VP.73 Characteristics of cardiac dysfunction in patients with Fukuyama congenital muscular dystrophy. Neuromuscul Disord 2022. [DOI: 10.1016/j.nmd.2022.07.335] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
6
|
Sunakawa Y, Satake H, Usher J, Jaimes Y, Miyamoto Y, Nakamura M, Kataoka M, Shiozawa M, Takagane A, Terazawa T, Watanabe T, Ishiguro K, Tanaka C, Takeuchi M, Fujii M, Danenberg K, Danenberg P, Lenz HJ, Sekikawa T, Ichikawa W. Dynamic changes in RAS gene status in circulating tumour DNA: a phase II trial of first-line FOLFOXIRI plus bevacizumab for RAS-mutant metastatic colorectal cancer (JACCRO CC-11). ESMO Open 2022; 7:100512. [PMID: 35688061 PMCID: PMC9271512 DOI: 10.1016/j.esmoop.2022.100512] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2022] [Revised: 04/26/2022] [Accepted: 04/28/2022] [Indexed: 12/22/2022] Open
Abstract
Background Few prospective studies have used liquid biopsy testing in RAS-mutant metastatic colorectal cancer (mCRC), and its clinical significance remains unknown. Therefore, this study aimed to carry out a biomarker analysis by liquid biopsy using updated data of the phase II trial of FOLFOXIRI plus bevacizumab as first-line chemotherapy for RAS-mutant mCRC. Materials and methods A total of 64 patients who received modified FOLFOXIRI regimen (irinotecan 150 mg/m2, oxaliplatin 85 mg/m2, levofolinate 200 mg/m2, and fluorouracil 2400 mg/m2) plus bevacizumab biweekly were enrolled. The primary endpoint was the objective response rate (ORR). Plasma samples were collected at pre-treatment, 8 weeks after treatment, and progression in participants included in the biomarker study. The levels of circulating tumour DNA (ctDNA) and specific KRAS and NRAS variants were evaluated using real-time PCR assays. Results There were 62 patients (median age: 62.5 years, 92% performance status 0, 27% right side) who were assessable for efficacy and 51 for biomarker analysis. ORR was 75.8% (95% confidence interval 65.1% to 86.5%). The median progression-free survival was 12.1 months, and the median overall survival (OS) was 30.2 months. In 78% of patients, RAS mutations disappeared in the ctDNA at 8 weeks after treatment; these patients tended to have better outcomes than those with RAS mutations. Interestingly, RAS mutations remained undetectable during progression in 62% of patients. Survival analysis indicated that the median OS from progression was significantly longer in patients with RAS mutation clearance than in those with RAS mutation in the ctDNA at disease progression (15.1 versus 7.3 months, hazard ratio: 0.21, P = 0.0046). Conclusions Our biomarker study demonstrated no RAS mutations in ctDNA at disease progression in 62% of patients with RAS-mutant mCRC. Both OS and post-progression survival were better in patients with clearance of RAS mutations in ctDNA after triplet-based chemotherapy. First-line FOLFOXIRI plus bevacizumab is effective for RAS-mutant mCRC with comparable efficacy in elderly patients. RAS mutations disappeared in ctDNA after intensive chemotherapy in 62% of patients with mCRC with RAS-mutant tumours. Survival time was longer in patients with RAS mutation clearance than in those with RAS mutations in ctDNA.
Collapse
|
7
|
Hatanaka Y, Niinuma T, Kitajima H, Nishiyama K, Maruyama R, Ishiguro K, Toyota M, Yamamoto E, Kai M, Yorozu A, Sekiguchi S, Ogi K, Dehari H, Idogawa M, Sasaki Y, Tokino T, Miyazaki A, Suzuki H. DLEU1 promotes oral squamous cell carcinoma progression by activating interferon-stimulated genes. Sci Rep 2021; 11:20438. [PMID: 34650128 PMCID: PMC8516910 DOI: 10.1038/s41598-021-99736-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2021] [Accepted: 09/30/2021] [Indexed: 11/09/2022] Open
Abstract
Long noncoding RNAs (lncRNAs) are deeply involved in cancer development. We previously reported that DLEU1 (deleted in lymphocytic leukemia 1) is one of the lncRNAs overexpressed in oral squamous cell carcinoma (OSCC) cells, where it exhibits oncogenic activity. In the present study, we further clarified the molecular function of DLEU1 in the pathogenesis of OSCC. Chromatin immunoprecipitation-sequencing (ChIP-seq) analysis revealed that DLEU1 knockdown induced significant changes in the levels of histone H3 lysine 4 trimethylation (H3K4me3) and H3K27 acetylation (H3K27ac) in OSCC cells. Notably, DLEU1 knockdown suppressed levels of H3K4me3/ H3K27ac and expression of a number of interferon-stimulated genes (ISGs), including IFIT1, IFI6 and OAS1, while ectopic DLEU1 expression activated these genes. Western blot analysis and reporter assays suggested that DLEU1 upregulates ISGs through activation of JAK-STAT signaling in OSCC cells. Moreover, IFITM1, one of the ISGs induced by DLUE1, was frequently overexpressed in primary OSCC tumors, and its knockdown inhibited OSCC cell proliferation, migration and invasion. These findings suggest that DLEU1 exerts its oncogenic effects, at least in part, through activation of a series ISGs in OSCC cells.
Collapse
Affiliation(s)
- Yui Hatanaka
- Department of Oral Surgery, Sapporo Medical University School of Medicine, Sapporo, Japan.,Department of Molecular Biology, Sapporo Medical University School of Medicine, S1, W17, Chuo-ku, Sapporo, 060-8556, Japan
| | - Takeshi Niinuma
- Department of Molecular Biology, Sapporo Medical University School of Medicine, S1, W17, Chuo-ku, Sapporo, 060-8556, Japan
| | - Hiroshi Kitajima
- Department of Molecular Biology, Sapporo Medical University School of Medicine, S1, W17, Chuo-ku, Sapporo, 060-8556, Japan
| | - Koyo Nishiyama
- Department of Oral Surgery, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Reo Maruyama
- Project for Cancer Epigenomics, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan
| | - Kazuya Ishiguro
- Department of Molecular Biology, Sapporo Medical University School of Medicine, S1, W17, Chuo-ku, Sapporo, 060-8556, Japan.,Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Mutsumi Toyota
- Department of Molecular Biology, Sapporo Medical University School of Medicine, S1, W17, Chuo-ku, Sapporo, 060-8556, Japan
| | - Eiichiro Yamamoto
- Department of Molecular Biology, Sapporo Medical University School of Medicine, S1, W17, Chuo-ku, Sapporo, 060-8556, Japan
| | - Masahiro Kai
- Department of Molecular Biology, Sapporo Medical University School of Medicine, S1, W17, Chuo-ku, Sapporo, 060-8556, Japan
| | - Akira Yorozu
- Department of Molecular Biology, Sapporo Medical University School of Medicine, S1, W17, Chuo-ku, Sapporo, 060-8556, Japan.,Department of Otolaryngology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Shohei Sekiguchi
- Department of Oral Surgery, Sapporo Medical University School of Medicine, Sapporo, Japan.,Department of Molecular Biology, Sapporo Medical University School of Medicine, S1, W17, Chuo-ku, Sapporo, 060-8556, Japan
| | - Kazuhiro Ogi
- Department of Oral Surgery, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Hironari Dehari
- Department of Oral Surgery, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Masashi Idogawa
- Department of Medical Genome Science, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Yasushi Sasaki
- Biology Division, Department of Liberal Arts and Sciences, Center for Medical Education, Sapporo Medical University, Sapporo, Japan
| | - Takashi Tokino
- Department of Medical Genome Science, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Akihiro Miyazaki
- Department of Oral Surgery, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Hiromu Suzuki
- Department of Molecular Biology, Sapporo Medical University School of Medicine, S1, W17, Chuo-ku, Sapporo, 060-8556, Japan.
| |
Collapse
|
8
|
Kawashima T, Ishiguro K, Sato F. Does the phenotypic morphology of the human brachial plexus reflect the theoretical development of concomitant regulation in thoracolumbar spines and nerves? Folia Morphol (Warsz) 2021; 81:884-899. [PMID: 34545555 DOI: 10.5603/fm.a2021.0094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2021] [Revised: 09/09/2021] [Accepted: 09/10/2021] [Indexed: 12/14/2022]
Abstract
BACKGROUND Experimental evidence identified that thoracolumbar mutants caused by Hox genes 7-10 mutants also involve a craniocaudal shift and/or the addition or reduction of segments of the limb plexus roots. This study investigated whether the theoretical concomitant shift of the brachial plexus roots in human different thoracolumbar counts is shared as confirmed in those of the human lumbosacral plexus. MATERIALS AND METHODS The phenotypic morphology of the brachial plexus and its arterial interaction on 20 sides of 10 atypical human thoracolumbar counts out of the 354 sides of the 177 cadavers, were compared with those of 52 sides of 26 cases in a typical human vertebral formula (7C_12T_5L_5S). RESULTS Regardless of the course and branching patterns of the axillary artery, our results showed that the main brachial plexus roots were composed of only five segments of the 5th-9th spinal nerves, with small contributions from the 4th and/or 10th nerves. This root composition is identical to a typical human thoracolumbar formula, and therefore, neither a craniocaudal shift nor additional/reduced main roots occurred in our thoracolumbar variants. CONCLUSIONS Unlike the concomitant shift of the lumbosacral plexus roots, our present cases suggest that the phenotypic morphology of the human brachial plexus may be less likely to show theoretical craniocaudal shifts, further data on the root changes in different vertebral formulae are needed for its accurate validation.
Collapse
Affiliation(s)
- T Kawashima
- Department of Anatomy, School of Medicine, Toho University, Tokyo, Japan.
| | - K Ishiguro
- Department of Anatomy, School of Medicine, Toho University, Tokyo, Japan
| | - F Sato
- Department of Anatomy, School of Medicine, Toho University, Tokyo, Japan
| |
Collapse
|
9
|
Agafonova N, Alexandrov A, Anokhina A, Aoki S, Ariga A, Ariga T, Bertolin A, Bozza C, Brugnera R, Buonaura A, Buontempo S, Chernyavskiy M, Chukanov A, Consiglio L, D'Ambrosio N, De Lellis G, De Serio M, Del Amo Sanchez P, Di Crescenzo A, Di Ferdinando D, Di Marco N, Dmitrievsky S, Dracos M, Duchesneau D, Dusini S, Dzhatdoev T, Ebert J, Ereditato A, Fini RA, Fornari F, Fukuda T, Galati G, Garfagnini A, Gentile V, Goldberg J, Gorbunov S, Gornushkin Y, Grella G, Guler AM, Gustavino C, Hagner C, Hara T, Hayakawa T, Hollnagel A, Ishiguro K, Iuliano A, Jakovčić K, Jollet C, Kamiscioglu C, Kamiscioglu M, Kim SH, Kitagawa N, Kliček B, Kodama K, Komatsu M, Kose U, Kreslo I, Laudisio F, Lauria A, Lavasa A, Longhin A, Loverre P, Malgin A, Mandrioli G, Matsuo T, Matveev V, Mauri N, Medinaceli E, Meregaglia A, Mikado S, Miyanishi M, Mizutani F, Monacelli P, Montesi MC, Morishima K, Muciaccia MT, Naganawa N, Naka T, Nakamura M, Nakano T, Niwa K, Ogawa S, Okateva N, Ozaki K, Paoloni A, Park BD, Pasqualini L, Pastore A, Patrizii L, Pessard H, Podgrudkov D, Polukhina N, Pozzato M, Pupilli F, Roda M, Roganova T, Rokujo H, Rosa G, Ryazhskaya O, Sato O, Shakirianova I, Schembri A, Shchedrina T, Shibayama E, Shibuya H, Shiraishi T, Šimko T, Simone S, Sirignano C, Sirri G, Sotnikov A, Spinetti M, Stanco L, Starkov N, Stellacci SM, Stipčević M, Strolin P, Takahashi S, Tenti M, Terranova F, Tioukov V, Tsanaktsidis I, Tufanli S, Ustyuzhanin A, Vasina S, Vidal García M, Vilain P, Voevodina E, Votano L, Vuilleumier JL, Wilquet G, Yoon CS. OPERA tau neutrino charged current interactions. Sci Data 2021; 8:218. [PMID: 34385471 PMCID: PMC8361145 DOI: 10.1038/s41597-021-00991-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2021] [Accepted: 07/01/2021] [Indexed: 11/08/2022] Open
Abstract
The OPERA experiment was designed to discover the vτ appearance in a vμ beam, due to neutrino oscillations. The detector, located in the underground Gran Sasso Laboratory, consisted of a nuclear photographic emulsion/lead target with a mass of about 1.25 kt, complemented by electronic detectors. It was exposed from 2008 to 2012 to the CNGS beam: an almost pure vμ beam with a baseline of 730 km, collecting a total of 1.8·1020 protons on target. The OPERA Collaboration eventually assessed the discovery of vμ→vτ oscillations with a statistical significance of 6.1 σ by observing ten vτ CC interaction candidates. These events have been published on the Open Data Portal at CERN. This paper provides a detailed description of the vτ data sample to make it usable by the whole community.
Collapse
Affiliation(s)
- N Agafonova
- INR - Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | | | - A Anokhina
- SINP MSU - Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, Moscow, Russia
| | - S Aoki
- Kobe University, Kobe, Japan
| | - A Ariga
- Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), University of Bern, Bern, Switzerland
| | - T Ariga
- Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), University of Bern, Bern, Switzerland
- Faculty of Arts and Science, Kyushu University, Fukuoka, Japan
| | | | - C Bozza
- Dipartimento di Fisica dell'Università di Salerno and "Gruppo Collegato" INFN, Fisciano (Salerno), Italy
| | - R Brugnera
- INFN Sezione di Padova, Padova, Italy
- Dipartimento di Fisica e Astronomia dell'Università di Padova, Padova, Italy
| | - A Buonaura
- INFN Sezione di Napoli, Napoli, Italy
- Dipartimento di Fisica dell'Università Federico II di Napoli, Napoli, Italy
- University of Liverpool, Liverpool, UK
| | | | - M Chernyavskiy
- LPI - Lebedev Physical Institute of the Russian Academy of Sciences, Moscow, Russia
| | - A Chukanov
- JINR - Joint Institute for Nuclear Research, Dubna, Russia
| | | | - N D'Ambrosio
- INFN - Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila), Italy
| | - G De Lellis
- INFN Sezione di Napoli, Napoli, Italy
- Dipartimento di Fisica dell'Università Federico II di Napoli, Napoli, Italy
| | - M De Serio
- Dipartimento di Fisica dell'Università di Bari, Bari, Italy
- INFN Sezione di Bari, Bari, Italy
| | - P Del Amo Sanchez
- LAPP, Université Savoie Mont Blanc, CNRS/IN2P3, Annecy-le-Vieux, France
| | - A Di Crescenzo
- INFN Sezione di Napoli, Napoli, Italy
- Dipartimento di Fisica dell'Università Federico II di Napoli, Napoli, Italy
| | | | - N Di Marco
- INFN - Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila), Italy
- GSSI - Gran Sasso Science Institute, L'Aquila, Italy
| | - S Dmitrievsky
- JINR - Joint Institute for Nuclear Research, Dubna, Russia.
| | - M Dracos
- IPHC, Université de Strasbourg, CNRS/IN2P3, Strasbourg, France
| | - D Duchesneau
- LAPP, Université Savoie Mont Blanc, CNRS/IN2P3, Annecy-le-Vieux, France
| | - S Dusini
- INFN Sezione di Padova, Padova, Italy
| | - T Dzhatdoev
- SINP MSU - Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, Moscow, Russia
| | - J Ebert
- Hamburg University, Hamburg, Germany
| | - A Ereditato
- Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), University of Bern, Bern, Switzerland
| | - R A Fini
- INFN Sezione di Bari, Bari, Italy
| | - F Fornari
- INFN Sezione di Bologna, Bologna, Italy
- Dipartimento di Fisica e Astronomia dell'Università di Bologna, Bologna, Italy
| | - T Fukuda
- Nagoya University, Nagoya, Japan
| | - G Galati
- INFN Sezione di Napoli, Napoli, Italy.
- Dipartimento di Fisica dell'Università Federico II di Napoli, Napoli, Italy.
| | - A Garfagnini
- INFN Sezione di Padova, Padova, Italy
- Dipartimento di Fisica e Astronomia dell'Università di Padova, Padova, Italy
| | - V Gentile
- GSSI - Gran Sasso Science Institute, L'Aquila, Italy
| | - J Goldberg
- Department of Physics, Technion, Haifa, Israel
| | - S Gorbunov
- LPI - Lebedev Physical Institute of the Russian Academy of Sciences, Moscow, Russia
| | - Y Gornushkin
- JINR - Joint Institute for Nuclear Research, Dubna, Russia
| | - G Grella
- Dipartimento di Fisica dell'Università di Salerno and "Gruppo Collegato" INFN, Fisciano (Salerno), Italy
| | - A M Guler
- METU - Middle East Technical University, Ankara, Turkey
| | | | - C Hagner
- Hamburg University, Hamburg, Germany
| | - T Hara
- Kobe University, Kobe, Japan
| | | | | | | | - A Iuliano
- INFN Sezione di Napoli, Napoli, Italy
- Dipartimento di Fisica dell'Università Federico II di Napoli, Napoli, Italy
| | - K Jakovčić
- Ruder Bošković Institute, Zagreb, Croatia
| | - C Jollet
- IPHC, Université de Strasbourg, CNRS/IN2P3, Strasbourg, France
| | - C Kamiscioglu
- METU - Middle East Technical University, Ankara, Turkey
- Ankara University, Ankara, Turkey
| | - M Kamiscioglu
- METU - Middle East Technical University, Ankara, Turkey
| | - S H Kim
- Gyeongsang National University, 900 Gazwa-dong, Jinju, 660-701, Korea
| | | | - B Kliček
- Center of Excellence for Advanced Materials and Sensing Devices, Ruder Bošković Institute, Zagreb, Croatia
| | - K Kodama
- Aichi University of Education, Kariya, (Aichi-Ken), Japan
| | | | - U Kose
- INFN Sezione di Padova, Padova, Italy
| | - I Kreslo
- Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), University of Bern, Bern, Switzerland
| | - F Laudisio
- INFN Sezione di Padova, Padova, Italy
- Dipartimento di Fisica e Astronomia dell'Università di Padova, Padova, Italy
| | - A Lauria
- INFN Sezione di Napoli, Napoli, Italy
- Dipartimento di Fisica dell'Università Federico II di Napoli, Napoli, Italy
| | | | - A Longhin
- INFN Sezione di Padova, Padova, Italy
- Dipartimento di Fisica e Astronomia dell'Università di Padova, Padova, Italy
| | | | - A Malgin
- INR - Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | | | - T Matsuo
- Toho University, Funabashi, Japan
| | - V Matveev
- INR - Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - N Mauri
- INFN Sezione di Bologna, Bologna, Italy
- Dipartimento di Fisica e Astronomia dell'Università di Bologna, Bologna, Italy
| | - E Medinaceli
- Istituto Nazionale di Astrofisica - Osservatorio di Astrofisica e Scienza dello Spazio Bologna, Bologna, Italy
| | - A Meregaglia
- IPHC, Université de Strasbourg, CNRS/IN2P3, Strasbourg, France
| | - S Mikado
- Nihon University, Narashino, Chiba, Japan
| | | | | | | | - M C Montesi
- INFN Sezione di Napoli, Napoli, Italy
- Dipartimento di Fisica dell'Università Federico II di Napoli, Napoli, Italy
| | | | - M T Muciaccia
- Dipartimento di Fisica dell'Università di Bari, Bari, Italy
- INFN Sezione di Bari, Bari, Italy
| | | | - T Naka
- Nagoya University, Nagoya, Japan
| | | | - T Nakano
- Nagoya University, Nagoya, Japan
| | - K Niwa
- Nagoya University, Nagoya, Japan
| | - S Ogawa
- Toho University, Funabashi, Japan
| | - N Okateva
- LPI - Lebedev Physical Institute of the Russian Academy of Sciences, Moscow, Russia
| | - K Ozaki
- Kobe University, Kobe, Japan
| | - A Paoloni
- INFN - Laboratori Nazionali di Frascati, Frascati (Roma), Italy
| | - B D Park
- Gyeongsang National University, 900 Gazwa-dong, Jinju, 660-701, Korea
| | - L Pasqualini
- INFN Sezione di Bologna, Bologna, Italy
- Dipartimento di Fisica e Astronomia dell'Università di Bologna, Bologna, Italy
| | | | | | - H Pessard
- LAPP, Université Savoie Mont Blanc, CNRS/IN2P3, Annecy-le-Vieux, France
| | - D Podgrudkov
- SINP MSU - Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, Moscow, Russia
| | - N Polukhina
- LPI - Lebedev Physical Institute of the Russian Academy of Sciences, Moscow, Russia
- MEPhI - Moscow Engineering Physics Institute, Moscow, Russia
| | - M Pozzato
- INFN Sezione di Bologna, Bologna, Italy
- Dipartimento di Fisica e Astronomia dell'Università di Bologna, Bologna, Italy
| | - F Pupilli
- INFN Sezione di Padova, Padova, Italy
| | - M Roda
- INFN Sezione di Padova, Padova, Italy
- Dipartimento di Fisica e Astronomia dell'Università di Padova, Padova, Italy
- Physik-Institut, Universitaet Zuerich, Zuerich, Switzerland
| | - T Roganova
- SINP MSU - Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, Moscow, Russia
| | - H Rokujo
- Nagoya University, Nagoya, Japan
| | - G Rosa
- INFN Sezione di Roma, Roma, Italy
| | - O Ryazhskaya
- INR - Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - O Sato
- Nagoya University, Nagoya, Japan
| | - I Shakirianova
- INR - Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - A Schembri
- INFN - Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila), Italy
| | - T Shchedrina
- LPI - Lebedev Physical Institute of the Russian Academy of Sciences, Moscow, Russia
| | | | | | | | | | - S Simone
- Dipartimento di Fisica dell'Università di Bari, Bari, Italy
- INFN Sezione di Bari, Bari, Italy
| | - C Sirignano
- INFN Sezione di Padova, Padova, Italy
- Dipartimento di Fisica e Astronomia dell'Università di Padova, Padova, Italy
| | - G Sirri
- INFN Sezione di Bologna, Bologna, Italy
| | - A Sotnikov
- JINR - Joint Institute for Nuclear Research, Dubna, Russia
| | - M Spinetti
- INFN - Laboratori Nazionali di Frascati, Frascati (Roma), Italy
| | - L Stanco
- INFN Sezione di Padova, Padova, Italy
| | - N Starkov
- LPI - Lebedev Physical Institute of the Russian Academy of Sciences, Moscow, Russia
| | - S M Stellacci
- Dipartimento di Fisica dell'Università di Salerno and "Gruppo Collegato" INFN, Fisciano (Salerno), Italy
| | - M Stipčević
- Center of Excellence for Advanced Materials and Sensing Devices, Ruder Bošković Institute, Zagreb, Croatia
| | - P Strolin
- INFN Sezione di Napoli, Napoli, Italy
- Dipartimento di Fisica dell'Università Federico II di Napoli, Napoli, Italy
| | | | - M Tenti
- INFN Sezione di Bologna, Bologna, Italy
| | - F Terranova
- Dipartimento di Fisica dell'Università di Milano-Bicocca, Milano, Italy
| | - V Tioukov
- INFN Sezione di Napoli, Napoli, Italy
| | | | - S Tufanli
- Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), University of Bern, Bern, Switzerland
- CERN, Geneva, Switzerland
| | - A Ustyuzhanin
- INFN Sezione di Napoli, Napoli, Italy
- HSE - National Research University Higher School of Economics, Moscow, Russia
| | - S Vasina
- JINR - Joint Institute for Nuclear Research, Dubna, Russia
| | | | - P Vilain
- IIHE, Université Libre de Bruxelles, Brussels, Belgium
| | | | - L Votano
- INFN - Laboratori Nazionali di Frascati, Frascati (Roma), Italy
| | - J L Vuilleumier
- Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), University of Bern, Bern, Switzerland
| | - G Wilquet
- IIHE, Université Libre de Bruxelles, Brussels, Belgium
| | - C S Yoon
- Gyeongsang National University, 900 Gazwa-dong, Jinju, 660-701, Korea
| |
Collapse
|
10
|
Sudo G, Aoki H, Yamamoto E, Takasawa A, Niinuma T, Yoshido A, Kitajima H, Yorozu A, Kubo T, Harada T, Ishiguro K, Kai M, Katanuma A, Yamano HO, Osanai M, Nakase H, Suzuki H. Activated macrophages promote invasion by early colorectal cancer via an interleukin 1β-serum amyloid A1 axis. Cancer Sci 2021; 112:4151-4165. [PMID: 34293235 PMCID: PMC8486202 DOI: 10.1111/cas.15080] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2021] [Revised: 07/06/2021] [Accepted: 07/14/2021] [Indexed: 01/15/2023] Open
Abstract
Submucosal invasion and lymph node metastasis are important issues affecting treatment options for early colorectal cancer (CRC). In this study, we aimed to unravel the molecular mechanism underlying the invasiveness of early CRCs. We performed RNA‐sequencing (RNA‐seq) with poorly differentiated components (PORs) and their normal counterparts isolated from T1 CRC tissues and detected significant upregulation of serum amyloid A1 (SAA1) in PORs. Immunohistochemical analysis revealed that SAA1 was specifically expressed in PORs at the invasive front of T1b CRCs. Upregulation of SAA1 in CRC cells promoted cell migration and invasion. Coculture experiments using CRC cell lines and THP‐1 cells suggested that interleukin 1β (IL‐1β) produced by macrophages induces SAA1 expression in CRC cells. Induction of SAA1 and promotion of CRC cell migration and invasion by macrophages were inhibited by blocking IL‐1β. These findings were supported by immunohistochemical analysis of primary T1 CRCs showing accumulation of M1‐like/M2‐like macrophages at SAA1‐positive invasive front regions. Moreover, SAA1 produced by CRC cells stimulated upregulation of matrix metalloproteinase‐9 in macrophages. Our data suggest that tumor‐associated macrophages at the invasive front of early CRCs promote cancer cell migration and invasion through induction of SAA1 and that SAA1 may be a predictive biomarker and a useful therapeutic target.
Collapse
Affiliation(s)
- Gota Sudo
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan.,Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Hironori Aoki
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan.,Center for Gastroenterology, Teine-Keijinkai Hospital, Sapporo, Japan
| | - Eiichiro Yamamoto
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan.,Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Akira Takasawa
- Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Takeshi Niinuma
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Ayano Yoshido
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Hiroshi Kitajima
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Akira Yorozu
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Toshiyuki Kubo
- Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Taku Harada
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan.,Center for Gastroenterology, Teine-Keijinkai Hospital, Sapporo, Japan
| | - Kazuya Ishiguro
- Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Masahiro Kai
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Akio Katanuma
- Center for Gastroenterology, Teine-Keijinkai Hospital, Sapporo, Japan
| | - Hiro-O Yamano
- Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Makoto Osanai
- Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Hiroshi Nakase
- Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Hiromu Suzuki
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan
| |
Collapse
|
11
|
Niinuma T, Kitajima H, Yamamoto E, Maruyama R, Aoki H, Harada T, Ishiguro K, Sudo G, Toyota M, Yoshido A, Kai M, Nakase H, Sugai T, Suzuki H. An Integrated Epigenome and Transcriptome Analysis to Clarify the Effect of Epigenetic Inhibitors on GIST. Anticancer Res 2021; 41:2817-2828. [PMID: 34083271 DOI: 10.21873/anticanres.15062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2021] [Revised: 05/12/2021] [Accepted: 05/13/2021] [Indexed: 11/10/2022]
Abstract
BACKGROUND/AIM Epigenetic alterations play an important role in the pathogenesis of gastrointestinal stromal tumors (GISTs). To obtain further insight into the GIST epigenome, we analyzed genome-wide histone modification and DNA methylation in GIST cells. MATERIALS AND METHODS To reverse epigenetic silencing, GIST-T1 cells were treated with a DNA methyltransferase inhibitor and a histone deacetylase inhibitor, and subsequently H3K4me3 levels, the DNA methylome, and the transcriptome were analyzed. RESULTS Treatment with epigenetic inhibitors not only up-regulated genes with DNA methylation, but also genes related to interferon signaling. ChIP-seq analysis revealed that drug treatment up-regulated H3K4me3 levels in retrotransposons, including endogenous retroviruses (ERV). Finally, utilizing the omics data, we found that hypermethylation of MEG3 is a frequent event and an indicator of poorer prognosis in GIST patients. CONCLUSION Epigenetic inhibitors may activate interferon signaling via viral mimicry in GIST cells. Moreover, epigenome data could be a useful resource to identify novel GIST-related genes.
Collapse
Affiliation(s)
- Takeshi Niinuma
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Hiroshi Kitajima
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Eiichiro Yamamoto
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan.,Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Reo Maruyama
- Project for Cancer Epigenomics, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan
| | - Hironori Aoki
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Taku Harada
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Kazuya Ishiguro
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Gota Sudo
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Mutsumi Toyota
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Ayano Yoshido
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Masahiro Kai
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Hiroshi Nakase
- Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Tamotsu Sugai
- Department of Molecular Diagnostic Pathology, Iwate Medical University, Morioka, Japan
| | - Hiromu Suzuki
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan;
| |
Collapse
|
12
|
Igarashi T, Ishiguro K, Takagi Y, Fujino M, Tsujisaki M. [Primary diffuse large B-cell lymphoma of the breast in a male patient with Sjögren's syndrome]. Rinsho Ketsueki 2021; 61:1584-1589. [PMID: 33298650 DOI: 10.11406/rinketsu.61.1584] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
When a 74-year-old male patient visited our hospital for the treatment of herpes zoster, his computed tomography (CT) revealed a mass in his right breast, axillary lymph node enlargement, and multiple lung nodules. A histological examination of the breast and lymph node biopsies revealed diffuse large B-cell lymphoma (DLBCL) while the bronchial and salivary gland biopsies showed secondary amyloidosis and Sjögren's syndrome (SjS). According to the Ann Arbor staging, the clinical stage of the lymphoma was evaluated as IIE. The patient achieved a complete remission after six cycles of rituximab, pirarubicin, cyclophosphamide, vincristine, and prednisolone (R-THP-COP) combined with intrathecal chemotherapy to prevent meningeal infiltration and irradiation after chemotherapy. Primary breast lymphoma was diagnosed within 2% of the breast tumor. Only sixteen male cases of breast lymphoma have been previously reported. In those reports, gynecomastia and hormonal therapy accounted for nine cases, but none of the cases coexisted with SjS. The present case is suggestive of the need to investigate possible autoimmune involvement in the development of lymphoma.
Collapse
|
13
|
Shichiji M, Kihara Y, Ishiguro K, Sato T, Takahashi M, Komaki H, Takada H, Kuru S, Matsumura T, Ishigaki K. FSHD / OPMD / MYOTONIC DYSTROPHY. Neuromuscul Disord 2020. [DOI: 10.1016/j.nmd.2020.08.236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
14
|
Murakami T, Sato T, Adachi M, Shichiji M, Ishiguro K, Kihara Y, Nagata S, Ishigaki K. CONGENITAL MUSCULAR DYSTROPHIES. Neuromuscul Disord 2020. [DOI: 10.1016/j.nmd.2020.08.197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
15
|
Sato T, Kihara Y, Ishiguro K, Shichiji M, Murakami T, Nagata S, Ishigaki K. CONGENITAL MUSCULAR DYSTROPHIES. Neuromuscul Disord 2020. [DOI: 10.1016/j.nmd.2020.08.201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
16
|
Suzuki H, Ueda N, Matsumura S, Masui M, Tsutsumi C, Mori M, Okubo Y, Ishiguro K. 246P A survey of breast cancer patients’ attitudes toward the breast reconstruction based on breast implant associated-anaplastic large cell lymphoma (BIA-ALCL). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.367] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
17
|
Ishiguro K, Sasaki Y, Takagi Y, Niinuma T, Suzuki H, Tokino T, Hayashi T, Takahashi T, Igarashi T, Matsuno Y. Aggressive variant of splenic marginal zone lymphoma characterized using a cancer panel test and treated with rituximab-containing chemotherapy: A case report. Medicine (Baltimore) 2020; 99:e21938. [PMID: 32871937 PMCID: PMC7458248 DOI: 10.1097/md.0000000000021938] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
RATIONALE Aggressive variant of splenic marginal zone lymphoma (AV-SMZL) is a very rare disease that is often associated with TP53 mutations and has a poor prognosis. On the other hand, recent advances in genome sequencing techniques enable us to understand the molecular characteristics of rare cancers such as AV-SMZL. Here we present a case of AV-SMZL analyzed using a genetic test. PATIENT CONCERNS A 66-year-old woman was admitted with splenomegaly and lymphocytosis. Computed tomography revealed marked splenomegaly without lymphadenopathy in any other areas. The serum soluble interleukin-2 receptor (sIL-2R) level was significantly elevated. Peripheral and bone marrow blood tests showed an increase in abnormal lymphocytes. DIAGNOSIS A splenectomy revealed an SMZL pattern with increased numbers of large cells and mitotic cells and a high Ki-67 positivity rate, which led to a diagnosis of AV-SMZL. Although TP53 mutation was not detected, mutations in NOTCH2, NCOA4, PTEN, EPHA3, and KMT2D were identified. Among these, the mutations in NCOA4, PTEN, and EPHA3 were novel pathogenic mutations in SMZL, which suggests they may be related to the aggressiveness and persistence of the disease. INTERVENTIONS The patient was administered a rituximab-containing regimen and rituximab-maintenance therapy. OUTCOMES The patient continues to exhibit a complete response. LESSONS This is a case of AV-SMZL in which a cancer panel test successfully detected genetic alterations that are potentially associated with its pathogenesis. These findings suggest that genetic analysis is useful for making diagnoses as well as for determining treatment strategies in AV-SMZL.
Collapse
Affiliation(s)
- Kazuya Ishiguro
- Department of Hematology, Tenshi Hospital
- Department of Molecular Biology, Sapporo Medical University School of Medicine
| | - Yasushi Sasaki
- Center for Medical Education, Sapporo Medical University
| | | | - Takeshi Niinuma
- Department of Molecular Biology, Sapporo Medical University School of Medicine
| | - Hiromu Suzuki
- Department of Molecular Biology, Sapporo Medical University School of Medicine
| | - Takashi Tokino
- Department of Medical Genome Sciences, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine
| | - Toshiaki Hayashi
- Department of Hematology, Teine Keijinkai Hospital, Sapporo, Japan
| | | | | | | |
Collapse
|
18
|
Sato T, Taniguchi N, Ishiguro K, Shichiji M, Murakami T, Awano H, Shirakawa T, Matsuo M, Nagata S, Ishigaki K. P.347Urinary titin fragment in Fukuyama congenital muscular dystrophy. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.461] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
19
|
Ishigaki K, Ihara C, Nakamura H, Mori-Yoshimura M, Maruo K, Murakami T, Sato T, Shichiji M, Ishiguro K, Nagata S, Kaiya H, Osawa M. FUKUYAMA CONGENITAL MUSCULAR DYSTROPHY. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.457] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
20
|
Ishiguro K, Nakayama T, Yoshioka M, Murakami T, Kajino S, Shichiji M, Sato T, Fukuyo N, Kuru S, Osawa M, Nagata S, Okubo M, Murakami N, Hayashi Y, Nishino I, Ishigaki K. EP.31Characteristic findings of skeletal muscle MRI in caveolinopathies. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.263] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
21
|
Niinuma T, Kitajima H, Kai M, Yamamoto E, Yorozu A, Ishiguro K, Sasaki H, Sudo G, Toyota M, Hatahira T, Maruyama R, Tokino T, Nakase H, Sugai T, Suzuki H. UHRF1 depletion and HDAC inhibition reactivate epigenetically silenced genes in colorectal cancer cells. Clin Epigenetics 2019; 11:70. [PMID: 31064417 PMCID: PMC6505222 DOI: 10.1186/s13148-019-0668-3] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2019] [Accepted: 04/23/2019] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND Ubiquitin-like protein containing PHD and RING finger domains 1 (UHRF1) is a major regulator of epigenetic mechanisms and is overexpressed in various human malignancies. In this study, we examined the involvement of UHRF1 in aberrant DNA methylation and gene silencing in colorectal cancer (CRC). RESULTS CRC cell lines were transiently transfected with siRNAs targeting UHRF1, after which DNA methylation was analyzed using dot blots, bisulfite pyrosequencing, and Infinium HumanMethylation450 BeadChip assays. Gene expression was analyzed using RT-PCR and gene expression microarrays. Depletion of UHRF1 rapidly induced genome-wide DNA demethylation in CRC cells. Infinium BeadChip assays and bisulfite pyrosequencing revealed significant demethylation across entire genomic regions, including CpG islands, gene bodies, intergenic regions, and repetitive elements. Despite the substantial demethylation, however, UHRF1 depletion only minimally reversed CpG island hypermethylation-associated gene silencing. By contrast, the combination of UHRF1 depletion and histone deacetylase (HDAC) inhibition reactivated the silenced genes and strongly suppressed CRC cell proliferation. The combination of UHRF1 depletion and HDAC inhibition also induced marked changes in the gene expression profiles such that cell cycle-related genes were strikingly downregulated. CONCLUSIONS Our results suggest that (i) maintenance of DNA methylation in CRC cells is highly dependent on UHRF1; (ii) UHRF1 depletion rapidly induces DNA demethylation, though it is insufficient to fully reactivate the silenced genes; and (iii) dual targeting of UHRF1 and HDAC may be an effective new therapeutic strategy.
Collapse
Affiliation(s)
- Takeshi Niinuma
- Department of Molecular Biology, Sapporo Medical University School of Medicine, S1, W17, Chuo-ku, Sapporo, 060-8556, Japan
| | - Hiroshi Kitajima
- Department of Molecular Biology, Sapporo Medical University School of Medicine, S1, W17, Chuo-ku, Sapporo, 060-8556, Japan
| | - Masahiro Kai
- Department of Molecular Biology, Sapporo Medical University School of Medicine, S1, W17, Chuo-ku, Sapporo, 060-8556, Japan
| | - Eiichiro Yamamoto
- Department of Molecular Biology, Sapporo Medical University School of Medicine, S1, W17, Chuo-ku, Sapporo, 060-8556, Japan.,Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Akira Yorozu
- Department of Molecular Biology, Sapporo Medical University School of Medicine, S1, W17, Chuo-ku, Sapporo, 060-8556, Japan
| | - Kazuya Ishiguro
- Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Hajime Sasaki
- Department of Molecular Biology, Sapporo Medical University School of Medicine, S1, W17, Chuo-ku, Sapporo, 060-8556, Japan.,Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Gota Sudo
- Department of Molecular Biology, Sapporo Medical University School of Medicine, S1, W17, Chuo-ku, Sapporo, 060-8556, Japan.,Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Mutsumi Toyota
- Department of Molecular Biology, Sapporo Medical University School of Medicine, S1, W17, Chuo-ku, Sapporo, 060-8556, Japan
| | - Tomo Hatahira
- Department of Molecular Biology, Sapporo Medical University School of Medicine, S1, W17, Chuo-ku, Sapporo, 060-8556, Japan
| | - Reo Maruyama
- Project for Cancer Epigenomics, Cancer Institute, Japanese Foundation for Cancer, Tokyo, Japan
| | - Takashi Tokino
- Department of Medical Genome Science, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Hiroshi Nakase
- Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Tamotsu Sugai
- Department of Molecular Diagnostic Pathology, Iwate Medical University, Morioka, Japan
| | - Hiromu Suzuki
- Department of Molecular Biology, Sapporo Medical University School of Medicine, S1, W17, Chuo-ku, Sapporo, 060-8556, Japan.
| |
Collapse
|
22
|
|
23
|
Ogawa Y, Naganuma A, Inagawa M, Iida T, Kimura M, Kumakura A, Yoshida T, Yamai N, Moroboshi A, Ueda R, Kawahara Y, Itou N, Shiozawa Y, Koyama Y, Funakoshi H, Manome M, Noguchi K, Kanai M, Ishiguro K, Ogawa T, Ishihara H. Effect of video endoscopic examination of swallowing function early after admission on length of hospital stay for patients with acute cerebral infarction: A retrospective study. Clin Nutr 2018. [DOI: 10.1016/j.clnu.2018.06.1150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
24
|
Uchida A, Ozawa M, Ueda Y, Murai Y, Nishimura Y, Ishimatsu H, Okouchi Y, Ishiguro K, Hamada Y, Sasamoto R, Watanabe M, Sano N, Miyamoto R, Inagawa S, Kikuchi K. Gastric adenocarcinoma of fundic gland mucosa type localized in the submucosa: A case report. Medicine (Baltimore) 2018; 97:e12341. [PMID: 30212986 PMCID: PMC6156021 DOI: 10.1097/md.0000000000012341] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
RATIONALE Gastric adenocarcinoma of fundic gland type (GA-FG) is a new histological type of gastric cancer manifesting with differentiation into a fundic gland. Furthermore, gastric adenocarcinoma of fundic gland mucosa type (GA-FGM) is a tumor that shows differentiation into not only a fundic gland but also foveolar epithelium and a mucous gland. These tumors tend to invade the submucosal layer. However, no cases of these tumors being localized only in the submucosa have been reported. Here, we present a case of GA-FGM localized in the submucosa and describe the cytological features of this tumor. To our knowledge, this is the first reported case of GA-FGM localized in the submucosa. PATIENT CONCERNS A man in his early 70s was referred to our institution because of the detection of a gastric submucosal tumor during a health checkup. DIAGNOSES Gastric adenocarcinoma of fundic gland mucosa type. INTERVENTIONS Endoscopic ultrasound-guided fine-needle aspiration (FNA), endoscopic submucosal dissection (ESD), and total gastrectomy with lymph node dissection were performed. OUTCOMES The FNA specimen showed epithelial cells with low-grade atypia. In the ESD specimen, adenocarcinoma showing a gastric fundic gland mucosa-like morphology was observed. Immunohistochemical analysis showed positive staining for pepsinogen I, H+/K+-adenosine triphosphatase, MUC6, and MUC5AC and negative staining for MUC2 and CD10, indicating tumor differentiation into fundic gland mucosa. Therefore, the tumor was diagnosed as GA-FGM, with localization in the submucosal layer. Total gastrectomy and lymph node dissection were performed because of the positive margins of the ESD specimen. Neither residual tumor nor lymph node metastasis was detected; however, many foci of heterotopic gastric glands (HGGs) were observed in the gastric wall, suggesting that GA-FGM arose from an HGG. After treatment, no recurrence was observed during a 1-year follow-up period. LESSONS Various tumors may arise from HGGs. Furthermore, when an FNA specimen shows gastric fundic gland mucosa-like epithelial cells with weak atypia, the possibility of GA-FG and GA-FGM should be considered.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | - Naoki Sano
- Department of Gastroenterological Surgery, Tsukuba Medical Center Hospital, Tsukuba, Ibaraki, Japan
| | - Ryoichi Miyamoto
- Department of Gastroenterological Surgery, Tsukuba Medical Center Hospital, Tsukuba, Ibaraki, Japan
| | - Satoshi Inagawa
- Department of Gastroenterological Surgery, Tsukuba Medical Center Hospital, Tsukuba, Ibaraki, Japan
| | | |
Collapse
|
25
|
Ishiguro K, Kitajima H, Niinuma T, Ishida T, Maruyama R, Ikeda H, Hayashi T, Sasaki H, Wakasugi H, Nishiyama K, Shindo T, Yamamoto E, Kai M, Sasaki Y, Tokino T, Nakase H, Suzuki H. DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling. Haematologica 2018; 104:155-165. [PMID: 30171029 PMCID: PMC6312027 DOI: 10.3324/haematol.2018.191262] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2018] [Accepted: 08/29/2018] [Indexed: 12/21/2022] Open
Abstract
Epigenetic alterations play an important role in the pathogenesis in multiple myeloma, but their biological and clinical relevance is not fully understood. Here, we show that DOT1L, which catalyzes methylation of histone H3 lysine 79, is required for myeloma cell survival. DOT1L expression levels were higher in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma than in normal plasma cells. Treatment with a DOT1L inhibitor induced cell cycle arrest and apoptosis in myeloma cells, and strongly suppressed cell proliferation in vitro. The anti-myeloma effect of DOT1L inhibition was confirmed in a mouse xenograft model. Chromatin immunoprecipitation-sequencing and microarray analysis revealed that DOT1L inhibition downregulated histone H3 lysine 79 dimethylation and expression of IRF4-MYC signaling genes in myeloma cells. In addition, DOT1L inhibition upregulated genes associated with immune responses and interferon signaling. Myeloma cells with histone modifier mutations or lower IRF4/MYC expression were less sensitive to DOT1L inhibition, but with prolonged treatment, anti-proliferative effects were achieved in these cells. Our data suggest that DOT1L plays an essential role in the development of multiple myeloma and that DOT1L inhibition may provide new therapies for myeloma treatment.
Collapse
Affiliation(s)
- Kazuya Ishiguro
- Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine.,Department of Molecular Biology, Sapporo Medical University School of Medicine
| | - Hiroshi Kitajima
- Department of Molecular Biology, Sapporo Medical University School of Medicine
| | - Takeshi Niinuma
- Department of Molecular Biology, Sapporo Medical University School of Medicine
| | - Tadao Ishida
- Department of Hematology, Japanese Red Cross Medical Center, Tokyo
| | - Reo Maruyama
- Project for Cancer Epigenomics, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo
| | - Hiroshi Ikeda
- Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine
| | - Toshiaki Hayashi
- Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine
| | - Hajime Sasaki
- Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine
| | - Hideki Wakasugi
- Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine
| | - Koyo Nishiyama
- Department of Molecular Biology, Sapporo Medical University School of Medicine
| | - Tetsuya Shindo
- Department of Molecular Biology, Sapporo Medical University School of Medicine
| | - Eiichiro Yamamoto
- Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine.,Department of Molecular Biology, Sapporo Medical University School of Medicine
| | - Masahiro Kai
- Department of Molecular Biology, Sapporo Medical University School of Medicine
| | - Yasushi Sasaki
- Department of Medical Genome Sciences, Research Institute for Frontier Medicine and Sapporo Medical University School of Medicine, Japan
| | - Takashi Tokino
- Department of Medical Genome Sciences, Research Institute for Frontier Medicine and Sapporo Medical University School of Medicine, Japan
| | - Hiroshi Nakase
- Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine
| | - Hiromu Suzuki
- Department of Molecular Biology, Sapporo Medical University School of Medicine
| |
Collapse
|
26
|
Agafonova N, Alexandrov A, Anokhina A, Aoki S, Ariga A, Ariga T, Bertolin A, Bozza C, Brugnera R, Buonaura A, Buontempo S, Chernyavskiy M, Chukanov A, Consiglio L, D'Ambrosio N, De Lellis G, De Serio M, Del Amo Sanchez P, Di Crescenzo A, Di Ferdinando D, Di Marco N, Dmitrievsky S, Dracos M, Duchesneau D, Dusini S, Dzhatdoev T, Ebert J, Ereditato A, Favier J, Fini RA, Fornari F, Fukuda T, Galati G, Garfagnini A, Gentile V, Goldberg J, Gorbunov S, Gornushkin Y, Grella G, Guler AM, Gustavino C, Hagner C, Hara T, Hayakawa T, Hollnagel A, Ishiguro K, Iuliano A, Jakovcic K, Jollet C, Kamiscioglu C, Kamiscioglu M, Kim SH, Kitagawa N, Klicek B, Kodama K, Komatsu M, Kose U, Kreslo I, Laudisio F, Lauria A, Ljubicic A, Longhin A, Loverre P, Malenica M, Malgin A, Mandrioli G, Matsuo T, Matveev V, Mauri N, Medinaceli E, Meregaglia A, Mikado S, Miyanishi M, Mizutani F, Monacelli P, Montesi MC, Morishima K, Muciaccia MT, Naganawa N, Naka T, Nakamura M, Nakano T, Niwa K, Ogawa S, Okateva N, Olchevsky A, Ozaki K, Paoloni A, Paparella L, Park BD, Pasqualini L, Pastore A, Patrizii L, Pessard H, Pistillo C, Podgrudkov D, Polukhina N, Pozzato M, Pupilli F, Roda M, Roganova T, Rokujo H, Rosa G, Ryazhskaya O, Sadovsky A, Sato O, Schembri A, Shakiryanova I, Shchedrina T, Shibayama E, Shibuya H, Shiraishi T, Simone S, Sirignano C, Sirri G, Sotnikov A, Spinetti M, Stanco L, Starkov N, Stellacci SM, Stipcevic M, Strolin P, Takahashi S, Tenti M, Terranova F, Tioukov V, Tufanli S, Ustyuzhanin A, Vasina S, Vilain P, Voevodina E, Votano L, Vuilleumier JL, Wilquet G, Wonsak B, Yoon CS. Final Results of the OPERA Experiment on ν_{τ} Appearance in the CNGS Neutrino Beam. Phys Rev Lett 2018; 120:211801. [PMID: 29883136 DOI: 10.1103/physrevlett.120.211801] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/16/2018] [Indexed: 06/08/2023]
Abstract
The OPERA experiment was designed to study ν_{μ}→ν_{τ} oscillations in the appearance mode in the CERN to Gran Sasso Neutrino beam (CNGS). In this Letter, we report the final analysis of the full data sample collected between 2008 and 2012, corresponding to 17.97×10^{19} protons on target. Selection criteria looser than in previous analyses have produced ten ν_{τ} candidate events, thus reducing the statistical uncertainty in the measurement of the oscillation parameters and of ν_{τ} properties. A multivariate approach for event identification has been applied to the candidate events and the discovery of ν_{τ} appearance is confirmed with an improved significance level of 6.1σ. |Δm_{32}^{2}| has been measured, in appearance mode, with an accuracy of 20%. The measurement of the ν_{τ} charged-current cross section, for the first time with a negligible contamination from ν[over ¯]_{τ}, and the first direct evidence for the ν_{τ} lepton number are also reported.
Collapse
Affiliation(s)
- N Agafonova
- INR-Institute for Nuclear Research of the Russian Academy of Sciences, RUS-117312 Moscow, Russia
| | | | - A Anokhina
- SINP MSU-Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, RUS-119991 Moscow, Russia
| | - S Aoki
- Kobe University, J-657-8501 Kobe, Japan
| | - A Ariga
- Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), University of Bern, CH-3012 Bern, Switzerland
| | - T Ariga
- Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), University of Bern, CH-3012 Bern, Switzerland
- Faculty of Arts and Science, Kyushu University, J-819-0395 Fukuoka, Japan
| | - A Bertolin
- INFN Sezione di Padova, I-35131 Padova, Italy
| | - C Bozza
- Dipartimento di Fisica dell'Università di Salerno and "Gruppo Collegato" INFN, I-84084 Fisciano (Salerno), Italy
| | - R Brugnera
- INFN Sezione di Padova, I-35131 Padova, Italy
- Dipartimento di Fisica e Astronomia dell'Università di Padova, I-35131 Padova, Italy
| | - A Buonaura
- INFN Sezione di Napoli, I-80126 Napoli, Italy
- Dipartimento di Fisica dell'Università Federico II di Napoli, I-80126 Napoli, Italy
| | - S Buontempo
- INFN Sezione di Napoli, I-80126 Napoli, Italy
| | - M Chernyavskiy
- LPI-Lebedev Physical Institute of the Russian Academy of Sciences, RUS-119991 Moscow, Russia
| | - A Chukanov
- JINR-Joint Institute for Nuclear Research, RUS-141980 Dubna, Russia
| | - L Consiglio
- INFN Sezione di Napoli, I-80126 Napoli, Italy
| | - N D'Ambrosio
- INFN-Laboratori Nazionali del Gran Sasso, I-67010 Assergi (L'Aquila), Italy
| | - G De Lellis
- INFN Sezione di Napoli, I-80126 Napoli, Italy
- Dipartimento di Fisica dell'Università Federico II di Napoli, I-80126 Napoli, Italy
| | - M De Serio
- Dipartimento di Fisica dell'Università di Bari, I-70126 Bari, Italy
- INFN Sezione di Bari, I-70126 Bari, Italy
| | - P Del Amo Sanchez
- LAPP, Université Savoie Mont Blanc, CNRS/IN2P3, F-74941 Annecy-le-Vieux, France
| | - A Di Crescenzo
- INFN Sezione di Napoli, I-80126 Napoli, Italy
- Dipartimento di Fisica dell'Università Federico II di Napoli, I-80126 Napoli, Italy
| | | | - N Di Marco
- INFN-Laboratori Nazionali del Gran Sasso, I-67010 Assergi (L'Aquila), Italy
| | - S Dmitrievsky
- JINR-Joint Institute for Nuclear Research, RUS-141980 Dubna, Russia
| | - M Dracos
- IPHC, Université de Strasbourg, CNRS/IN2P3, F-67037 Strasbourg, France
| | - D Duchesneau
- LAPP, Université Savoie Mont Blanc, CNRS/IN2P3, F-74941 Annecy-le-Vieux, France
| | - S Dusini
- INFN Sezione di Padova, I-35131 Padova, Italy
| | - T Dzhatdoev
- SINP MSU-Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, RUS-119991 Moscow, Russia
| | - J Ebert
- Hamburg University, D-22761 Hamburg, Germany
| | - A Ereditato
- Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), University of Bern, CH-3012 Bern, Switzerland
| | - J Favier
- LAPP, Université Savoie Mont Blanc, CNRS/IN2P3, F-74941 Annecy-le-Vieux, France
| | - R A Fini
- INFN Sezione di Bari, I-70126 Bari, Italy
| | - F Fornari
- INFN Sezione di Bologna, I-40127 Bologna, Italy
- Dipartimento di Fisica e Astronomia dell'Università di Bologna, I-40127 Bologna, Italy
| | - T Fukuda
- Nagoya University, J-464-8602 Nagoya, Japan
| | - G Galati
- INFN Sezione di Napoli, I-80126 Napoli, Italy
- Dipartimento di Fisica dell'Università Federico II di Napoli, I-80126 Napoli, Italy
| | - A Garfagnini
- INFN Sezione di Padova, I-35131 Padova, Italy
- Dipartimento di Fisica e Astronomia dell'Università di Padova, I-35131 Padova, Italy
| | - V Gentile
- GSSI-Gran Sasso Science Institute, I-40127 L'Aquila, Italy
| | - J Goldberg
- Department of Physics, Technion, IL-32000 Haifa, Israel
| | - S Gorbunov
- LPI-Lebedev Physical Institute of the Russian Academy of Sciences, RUS-119991 Moscow, Russia
| | - Y Gornushkin
- JINR-Joint Institute for Nuclear Research, RUS-141980 Dubna, Russia
| | - G Grella
- Dipartimento di Fisica dell'Università di Salerno and "Gruppo Collegato" INFN, I-84084 Fisciano (Salerno), Italy
| | - A M Guler
- METU-Middle East Technical University, TR-06800 Ankara, Turkey
| | | | - C Hagner
- Hamburg University, D-22761 Hamburg, Germany
| | - T Hara
- Kobe University, J-657-8501 Kobe, Japan
| | - T Hayakawa
- Nagoya University, J-464-8602 Nagoya, Japan
| | - A Hollnagel
- Hamburg University, D-22761 Hamburg, Germany
| | - K Ishiguro
- Nagoya University, J-464-8602 Nagoya, Japan
| | - A Iuliano
- INFN Sezione di Napoli, I-80126 Napoli, Italy
- Dipartimento di Fisica dell'Università Federico II di Napoli, I-80126 Napoli, Italy
| | - K Jakovcic
- Ruder Bošković Institute, HR-10002 Zagreb, Croatia
| | - C Jollet
- IPHC, Université de Strasbourg, CNRS/IN2P3, F-67037 Strasbourg, France
| | - C Kamiscioglu
- METU-Middle East Technical University, TR-06800 Ankara, Turkey
- Ankara University, TR-06560 Ankara, Turkey
| | - M Kamiscioglu
- METU-Middle East Technical University, TR-06800 Ankara, Turkey
| | - S H Kim
- Gyeongsang National University, 900 Gazwa-dong, Jinju 660-701, Korea
| | - N Kitagawa
- Nagoya University, J-464-8602 Nagoya, Japan
| | - B Klicek
- Center of Excellence for Advanced Materials and Sensing Devices, Ruder Bośković Institute, HR-10002 Zagreb, Croatia
| | - K Kodama
- Aichi University of Education, J-448-8542 Kariya (Aichi-Ken), Japan
| | - M Komatsu
- Nagoya University, J-464-8602 Nagoya, Japan
| | - U Kose
- INFN Sezione di Padova, I-35131 Padova, Italy
| | - I Kreslo
- Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), University of Bern, CH-3012 Bern, Switzerland
| | - F Laudisio
- INFN Sezione di Padova, I-35131 Padova, Italy
- Dipartimento di Fisica e Astronomia dell'Università di Padova, I-35131 Padova, Italy
| | - A Lauria
- INFN Sezione di Napoli, I-80126 Napoli, Italy
- Dipartimento di Fisica dell'Università Federico II di Napoli, I-80126 Napoli, Italy
| | - A Ljubicic
- Ruder Bošković Institute, HR-10002 Zagreb, Croatia
| | - A Longhin
- INFN Sezione di Padova, I-35131 Padova, Italy
- Dipartimento di Fisica e Astronomia dell'Università di Padova, I-35131 Padova, Italy
| | - P Loverre
- INFN Sezione di Roma, I-00185 Roma, Italy
| | - M Malenica
- Ruder Bošković Institute, HR-10002 Zagreb, Croatia
| | - A Malgin
- INR-Institute for Nuclear Research of the Russian Academy of Sciences, RUS-117312 Moscow, Russia
| | - G Mandrioli
- INFN Sezione di Bologna, I-40127 Bologna, Italy
| | - T Matsuo
- Toho University, J-274-8510 Funabashi, Japan
| | - V Matveev
- INR-Institute for Nuclear Research of the Russian Academy of Sciences, RUS-117312 Moscow, Russia
| | - N Mauri
- INFN Sezione di Bologna, I-40127 Bologna, Italy
- Dipartimento di Fisica e Astronomia dell'Università di Bologna, I-40127 Bologna, Italy
| | - E Medinaceli
- INFN Sezione di Padova, I-35131 Padova, Italy
- Dipartimento di Fisica e Astronomia dell'Università di Padova, I-35131 Padova, Italy
| | - A Meregaglia
- IPHC, Université de Strasbourg, CNRS/IN2P3, F-67037 Strasbourg, France
| | - S Mikado
- Nihon University, J-275-8576 Narashino, Chiba, Japan
| | | | | | | | - M C Montesi
- INFN Sezione di Napoli, I-80126 Napoli, Italy
- Dipartimento di Fisica dell'Università Federico II di Napoli, I-80126 Napoli, Italy
| | | | - M T Muciaccia
- Dipartimento di Fisica dell'Università di Bari, I-70126 Bari, Italy
- INFN Sezione di Bari, I-70126 Bari, Italy
| | - N Naganawa
- Nagoya University, J-464-8602 Nagoya, Japan
| | - T Naka
- Nagoya University, J-464-8602 Nagoya, Japan
| | - M Nakamura
- Nagoya University, J-464-8602 Nagoya, Japan
| | - T Nakano
- Nagoya University, J-464-8602 Nagoya, Japan
| | - K Niwa
- Nagoya University, J-464-8602 Nagoya, Japan
| | - S Ogawa
- Toho University, J-274-8510 Funabashi, Japan
| | - N Okateva
- LPI-Lebedev Physical Institute of the Russian Academy of Sciences, RUS-119991 Moscow, Russia
| | - A Olchevsky
- JINR-Joint Institute for Nuclear Research, RUS-141980 Dubna, Russia
| | - K Ozaki
- Kobe University, J-657-8501 Kobe, Japan
| | - A Paoloni
- INFN-Laboratori Nazionali di Frascati dell'INFN, I-00044 Frascati (Roma), Italy
| | - L Paparella
- Dipartimento di Fisica dell'Università di Bari, I-70126 Bari, Italy
- INFN Sezione di Bari, I-70126 Bari, Italy
| | - B D Park
- Gyeongsang National University, 900 Gazwa-dong, Jinju 660-701, Korea
| | - L Pasqualini
- INFN Sezione di Bologna, I-40127 Bologna, Italy
- Dipartimento di Fisica e Astronomia dell'Università di Bologna, I-40127 Bologna, Italy
| | - A Pastore
- INFN Sezione di Bari, I-70126 Bari, Italy
| | - L Patrizii
- INFN Sezione di Bologna, I-40127 Bologna, Italy
| | - H Pessard
- LAPP, Université Savoie Mont Blanc, CNRS/IN2P3, F-74941 Annecy-le-Vieux, France
| | - C Pistillo
- Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), University of Bern, CH-3012 Bern, Switzerland
| | - D Podgrudkov
- SINP MSU-Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, RUS-119991 Moscow, Russia
| | - N Polukhina
- LPI-Lebedev Physical Institute of the Russian Academy of Sciences, RUS-119991 Moscow, Russia
- MEPhI-Moscow Engineering Physics Institute, RUS-115409 Moscow, Russia
| | - M Pozzato
- INFN Sezione di Bologna, I-40127 Bologna, Italy
- Dipartimento di Fisica e Astronomia dell'Università di Bologna, I-40127 Bologna, Italy
| | - F Pupilli
- INFN Sezione di Padova, I-35131 Padova, Italy
| | - M Roda
- INFN Sezione di Padova, I-35131 Padova, Italy
- Dipartimento di Fisica e Astronomia dell'Università di Padova, I-35131 Padova, Italy
| | - T Roganova
- SINP MSU-Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, RUS-119991 Moscow, Russia
| | - H Rokujo
- Nagoya University, J-464-8602 Nagoya, Japan
| | - G Rosa
- INFN Sezione di Roma, I-00185 Roma, Italy
| | - O Ryazhskaya
- INR-Institute for Nuclear Research of the Russian Academy of Sciences, RUS-117312 Moscow, Russia
| | - A Sadovsky
- JINR-Joint Institute for Nuclear Research, RUS-141980 Dubna, Russia
| | - O Sato
- Nagoya University, J-464-8602 Nagoya, Japan
| | - A Schembri
- INFN-Laboratori Nazionali del Gran Sasso, I-67010 Assergi (L'Aquila), Italy
| | - I Shakiryanova
- INR-Institute for Nuclear Research of the Russian Academy of Sciences, RUS-117312 Moscow, Russia
| | - T Shchedrina
- LPI-Lebedev Physical Institute of the Russian Academy of Sciences, RUS-119991 Moscow, Russia
| | | | - H Shibuya
- Toho University, J-274-8510 Funabashi, Japan
| | | | - S Simone
- Dipartimento di Fisica dell'Università di Bari, I-70126 Bari, Italy
- INFN Sezione di Bari, I-70126 Bari, Italy
| | - C Sirignano
- INFN Sezione di Padova, I-35131 Padova, Italy
- Dipartimento di Fisica e Astronomia dell'Università di Padova, I-35131 Padova, Italy
| | - G Sirri
- INFN Sezione di Bologna, I-40127 Bologna, Italy
| | - A Sotnikov
- JINR-Joint Institute for Nuclear Research, RUS-141980 Dubna, Russia
| | - M Spinetti
- INFN-Laboratori Nazionali di Frascati dell'INFN, I-00044 Frascati (Roma), Italy
| | - L Stanco
- INFN Sezione di Padova, I-35131 Padova, Italy
| | - N Starkov
- LPI-Lebedev Physical Institute of the Russian Academy of Sciences, RUS-119991 Moscow, Russia
| | - S M Stellacci
- Dipartimento di Fisica dell'Università di Salerno and "Gruppo Collegato" INFN, I-84084 Fisciano (Salerno), Italy
| | - M Stipcevic
- Center of Excellence for Advanced Materials and Sensing Devices, Ruder Bośković Institute, HR-10002 Zagreb, Croatia
| | - P Strolin
- INFN Sezione di Napoli, I-80126 Napoli, Italy
- Dipartimento di Fisica dell'Università Federico II di Napoli, I-80126 Napoli, Italy
| | | | - M Tenti
- INFN Sezione di Bologna, I-40127 Bologna, Italy
| | - F Terranova
- Dipartimento di Fisica dell'Università di Milano-Bicocca, I-20126 Milano, Italy
| | - V Tioukov
- INFN Sezione di Napoli, I-80126 Napoli, Italy
| | - S Tufanli
- Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), University of Bern, CH-3012 Bern, Switzerland
| | - A Ustyuzhanin
- INFN Sezione di Napoli, I-80126 Napoli, Italy
- HSE-National Research University Higher School of Economics, RUS-101000, Moscow, Russia
| | - S Vasina
- JINR-Joint Institute for Nuclear Research, RUS-141980 Dubna, Russia
| | - P Vilain
- IIHE, Université Libre de Bruxelles, B-1050 Brussels, Belgium
| | - E Voevodina
- INFN Sezione di Napoli, I-80126 Napoli, Italy
| | - L Votano
- INFN-Laboratori Nazionali di Frascati dell'INFN, I-00044 Frascati (Roma), Italy
| | - J L Vuilleumier
- Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), University of Bern, CH-3012 Bern, Switzerland
| | - G Wilquet
- IIHE, Université Libre de Bruxelles, B-1050 Brussels, Belgium
| | - B Wonsak
- Hamburg University, D-22761 Hamburg, Germany
| | - C S Yoon
- Gyeongsang National University, 900 Gazwa-dong, Jinju 660-701, Korea
| |
Collapse
|
27
|
Ishiguro K, Hayashi T, Yokoyama Y, Aoki Y, Onodera K, Ikeda H, Ishida T, Nakase H. Elevation of Plasmin-α2-plasmin Inhibitor Complex Predicts the Diagnosis of Systemic AL Amyloidosis in Patients with Monoclonal Protein. Intern Med 2018; 57:783-788. [PMID: 29021469 PMCID: PMC5891514 DOI: 10.2169/internalmedicine.8999-17] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
Objective The complication of systemic immunoglobulin light chain (AL) amyloidosis in patients with monoclonal immunoglobulin affects the prognosis, but amyloid deposition in tissues is sometimes difficult to detect due to bleeding tendencies and preferential distributions. However, fibrinolysis is known to be exacerbated in patients with systemic AL amyloidosis specifically. We therefore explored new biomarkers for predicting a diagnosis of systemic AL amyloidosis focusing on coagulation and fibrinolysis markers. Methods We reviewed the clinical features and treatment outcomes of patients with serum monoclonal protein, including primary systemic AL amyloidosis and multiple myeloma (MM), treated at our hospital between January 2008 and December 2014. Results Among several biomarkers, only the serum level of plasmin-α2-plasmin inhibitor complex (PIC) in patients with systemic AL amyloidosis (n=26) at the diagnosis was significantly higher than in patients with MM without AL amyloidosis (n=26) (mean±standard deviation, 3.69±2.82 μg/mL vs. 1.23±0.97 μg/mL, p<0.01). The cut-off for predicting a diagnosis of systemic AL amyloidosis in patients with serum monoclonal protein was 1.72 μg/mL with 84.6% sensitivity and 80.8% specificity. Hepatic involvement resulted in a significantly higher PIC level than no involvement in patients with systemic AL amyloidosis. The serum PIC level was also associated with the hematological response of systemic AL amyloidosis. Conclusion PIC is a useful biomarker for the diagnosis and management of patients with systemic AL amyloidosis.
Collapse
Affiliation(s)
- Kazuya Ishiguro
- Department of Gastroenterology, Rheumatology, and Clinical Immunology, Sapporo Medical University School of Medicine, Japan
| | - Toshiaki Hayashi
- Department of Gastroenterology, Rheumatology, and Clinical Immunology, Sapporo Medical University School of Medicine, Japan
| | - Yoshihiro Yokoyama
- Department of Gastroenterology, Rheumatology, and Clinical Immunology, Sapporo Medical University School of Medicine, Japan
| | - Yuka Aoki
- Department of Gastroenterology, Rheumatology, and Clinical Immunology, Sapporo Medical University School of Medicine, Japan
| | - Kei Onodera
- Department of Gastroenterology, Rheumatology, and Clinical Immunology, Sapporo Medical University School of Medicine, Japan
| | - Hiroshi Ikeda
- Department of Gastroenterology, Rheumatology, and Clinical Immunology, Sapporo Medical University School of Medicine, Japan
| | - Tadao Ishida
- Department of Gastroenterology, Rheumatology, and Clinical Immunology, Sapporo Medical University School of Medicine, Japan
| | - Hiroshi Nakase
- Department of Gastroenterology, Rheumatology, and Clinical Immunology, Sapporo Medical University School of Medicine, Japan
| |
Collapse
|
28
|
Kurihara H, Maruyama R, Ishiguro K, Kanno S, Yamamoto I, Ishigami K, Mitsuhashi K, Igarashi H, Ito M, Tanuma T, Sukawa Y, Okita K, Hasegawa T, Imai K, Yamamoto H, Shinomura Y, Nosho K. The relationship between EZH2 expression and microRNA-31 in colorectal cancer and the role in evolution of the serrated pathway. Oncotarget 2017; 7:12704-17. [PMID: 26871294 PMCID: PMC4914316 DOI: 10.18632/oncotarget.7260] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2015] [Accepted: 01/27/2016] [Indexed: 02/07/2023] Open
Abstract
Polycomb group protein enhancer of zeste homolog 2 (EZH2) is a methyltransferase that correlates with the regulation of invasion and metastasis and is overexpressed in human cancers such as colorectal cancer. MicroRNA-31 (miR-31) plays an oncogenic role and is associated with BRAF mutation and poor prognosis in colorectal cancer. EZH2 is functionally considered to suppress miR-31 expression in human cancers; however, no study has reported its relationship with colon cancer. We therefore evaluated EZH2 expression using immunohistochemistry and assessed miR-31 and epigenetic alterations using 301 colorectal carcinomas and 207 premalignant lesions. Functional analysis was performed to identify the association between EZH2 and miR-31 using cancer cell lines. In the current study, negative, weak, moderate, and strong EZH2 expressions were observed in 15%, 19%, 25%, and 41% of colorectal cancers, respectively. EZH2 was inversely associated with miR-31 (P < 0.0001), independent of clinicopathological and molecular features. In a multivariate stage-stratified analysis, high EZH2 expression was related to favorable prognosis (P = 0.0022). Regarding premalignant lesions, negative EZH2 expression was frequently detected in sessile serrated adenomas/polyps (SSA/Ps) (76%; P < 0.0001) compared with hyperplastic polyps, traditional serrated adenomas, and non-serrated adenomas (25–36%). Functional analysis demonstrated that the knockdown of EZH2 increased miR-31 expression. In conclusion, an inverse association was identified between EZH2 and miR-31 in colorectal cancers. Our data also showed that upregulation of EZH2 expression may be rare in SSA/Ps. These results suggest that EZH2 suppresses miR-31 in colorectal cancer and may correlate with differentiation and evolution of serrated pathway.
Collapse
Affiliation(s)
- Hiroyoshi Kurihara
- Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Reo Maruyama
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Kazuya Ishiguro
- Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Shinichi Kanno
- Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Itaru Yamamoto
- Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Keisuke Ishigami
- Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Kei Mitsuhashi
- Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Hisayoshi Igarashi
- Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan.,The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Miki Ito
- Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Tokuma Tanuma
- Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Yasutaka Sukawa
- Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Kenji Okita
- Department of Surgery, Surgical Oncology and Science, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Tadashi Hasegawa
- Department of Surgical Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Kohzoh Imai
- The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Hiroyuki Yamamoto
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
| | | | - Katsuhiko Nosho
- Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan
| |
Collapse
|
29
|
Takahashi T, Ishiguro K, Maruyama Y, Kazama T, Takamura T, Itoh H, Yoshimoto M, Tsujisaki M, Ohba G. Near Tetraploidy Acute Myeloid Leukemia in Long-term Remission with Persistent Clonal Hematopoiesis with del(20)(q12q13). Intern Med 2017. [PMID: 29093395 DOI: 10.2169/internalmedicine.9122-17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Patients with near tetraploidy/tetraploidy (NT/T)-acute myeloid leukemia (AML) are rare and generally show poor survival. A 62-year-old man was referred to our hospital with pancytopenia. A bone marrow examination revealed the proliferation of extremely large blasts, and led to the diagnosis of AML M0. A cytogenetic analysis showed an NT-karyotype of 91, XXYY, -5, add(18)(p21),del(20)(q12q13) ×2. Complete remission was achieved with single remission induction chemotherapy. Although consolidation chemotherapies were not available because of his critical condition, he remained in remission and survived for more than 40 months without cytopenia. However, repeated bone marrow examinations showed persistent clonal hematopoiesis with del(20)(q12q13) without apparent myelodysplasia.
Collapse
Affiliation(s)
| | | | | | - Tomoe Kazama
- Department of Gastroenterology, Tenshi Hospital, Japan
| | | | - Hideto Itoh
- Department of Gastroenterology, Tenshi Hospital, Japan
| | | | | | - Go Ohba
- Department of Surgery, Tenshi Hospital, Japan
| |
Collapse
|
30
|
Murakami T, Ishigaki K, Ishiguro K, Sato T, Shichiji M, Nagata S, Uchiyama T, Kuru S, Nakayama T. Assessment of skeletal muscle in patients with Fukuyama congenital muscular dystrophy (FCMD) using bioelectrical impedance analysis (BIA). J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.2308] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
31
|
Sato T, Adachi M, Nakamura K, Zushi M, Goto K, Murakami T, Ishiguro K, Shichiji M, Saito K, Ikai T, Osawa M, Kondo I, Nagata S, Ishigaki K. The gross motor function measure is valid for Fukuyama congenital muscular dystrophy. Neuromuscul Disord 2017. [DOI: 10.1016/j.nmd.2017.06.472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
32
|
Ishiguro K, Murakami T, Kajino S, Shichiji M, Sato T, Hayashi Y, Nakayama T, Kuru S, Osawa M, Nagata S, Ishigaki K. Characteristic findings of skeletal muscle MRI in childhood-onset Rippling muscle disease. Neuromuscul Disord 2017. [DOI: 10.1016/j.nmd.2017.06.179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
33
|
Murakami T, Ishigai K, Ishiguro K, Sato T, Shichiji M, Ikeda M, Nagata S, Uchida T, Kuru S, Nakayama T. Evaluation of skeletal muscle in patients with Fukuyama congenital muscular dystrophy (FCMD) using bioelectrical impedance analysis. Neuromuscul Disord 2017. [DOI: 10.1016/j.nmd.2017.06.473] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
34
|
Shichiji M, Ishigaki K, Ishiguro K, Sato T, Murakami T, Matsumura T, Osawa M, Nagata S. Results of a Japanese nationwide survey on congenital myotonic dystrophy. Neuromuscul Disord 2017. [DOI: 10.1016/j.nmd.2017.06.305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
35
|
Yamamoto I, Nosho K, Kanno S, Igarashi H, Kurihara H, Ishigami K, Ishiguro K, Mitsuhashi K, Maruyama R, Koide H, Okuda H, Hasegawa T, Sukawa Y, Okita K, Takemasa I, Yamamoto H, Shinomura Y, Nakase H. EZH2 expression is a prognostic biomarker in patients with colorectal cancer treated with anti-EGFR therapeutics. Oncotarget 2017; 8:17810-17818. [PMID: 28147317 PMCID: PMC5392288 DOI: 10.18632/oncotarget.14863] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2016] [Accepted: 01/16/2017] [Indexed: 01/09/2023] Open
Abstract
The polycomb group protein enhancer of zeste homolog 2 (EZH2) is a methyltransferase that suppresses microRNA-31 (miR-31) in various human malignancies including colorectal cancer. We recently suggested that miR-31 regulates the signaling pathway downstream of epidermal growth factor receptor (EGFR) in colorectal cancer. Therefore, we conducted this study for assessing the relationship between EZH2 expression and clinical outcomes in patients with colorectal cancer treated with anti-EGFR therapeutics. We immunohistochemically evaluated EZH2 expression and assessed miR-31 and gene mutations [KRAS (codon 61/146), NRAS (codon 12/13/61), and BRAF (codon 600)] in 109 patients with colorectal cancer harboring KRAS (codon 12/13) wild-type. We also evaluated the progression-free survival (PFS) and overall survival (OS). In the result, low EZH2 expression was significantly associated with shorter PFS (log-rank test: P = 0.023) and OS (P = 0.036) in patients with colorectal cancer. In the low-miR-31-expression group and the KRAS (codon 61/146), NRAS, and BRAF wild-type groups, a significantly shorter PFS (P = 0.022, P = 0.039, P = 0.021, and P = 0.036, respectively) was observed in the EZH2 low-expression groups than in the high-expression groups. In the multivariate analysis, low EZH2 expression was associated with a shorter PFS (P = 0.046), independent of the mutational status and miR-31. In conclusion, EZH2 expression was associated with survival in patients with colorectal cancer who were treated with anti-EGFR therapeutics. Moreover, low EZH2 expression was independently associated with shorter PFS in patients with cancer, suggesting that EZH2 expression is a useful additional prognostic biomarker for anti-EGFR therapy.
Collapse
Affiliation(s)
- Itaru Yamamoto
- Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Katsuhiko Nosho
- Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Shinichi Kanno
- Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Hisayoshi Igarashi
- Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Hiroyoshi Kurihara
- Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Keisuke Ishigami
- Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Kazuya Ishiguro
- Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Kei Mitsuhashi
- Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Reo Maruyama
- Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Hideyuki Koide
- Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Hiroyuki Okuda
- Department of Oncology, Keiyukai Sapporo Hospital, Sapporo, Japan
| | - Tadashi Hasegawa
- Department of Surgical Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Yasutaka Sukawa
- Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Kenji Okita
- Department of Surgery, Surgical Oncology and Science, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Ichiro Takemasa
- Department of Surgery, Surgical Oncology and Science, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Hiroyuki Yamamoto
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
| | | | - Hiroshi Nakase
- Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| |
Collapse
|
36
|
Ogawa Y, Naganuma A, Inagawa M, Iida T, Kimura M, Kumakura A, Yoshida T, Nakamura H, Moroboshi A, Ueda R, Kawahara Y, Sekine S, Shiozawa Y, Koyama Y, Funakoshi H, Tanaka H, Kanai M, Ishiguro K, Ogawa T, Ishihara H. MON-P026: Early Evaluation of the Swallowing Function Can Shorten Hospitalisation Period for Patients with Acute Cerebral infarction: A Historical Control Study. Clin Nutr 2017. [DOI: 10.1016/s0261-5614(17)31057-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
37
|
Okamura N, Ishiguro K, Maeda T, Yagi S. Luminescent Properties of Novel Bis-cyclometalated Iridium(III) Complex Bearing a Phosphine Oxide-appended Diketonate Ligand for Solution-processed Multilayer OLEDs. CHEM LETT 2017. [DOI: 10.1246/cl.170317] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Affiliation(s)
- Naoki Okamura
- Department of Applied Chemistry, Graduate School of Engineering, Osaka Prefecture University, 1-1 Gakuen-cho, Naka-ku, Sakai, Osaka 599-8531
| | - Kazuya Ishiguro
- Department of Applied Chemistry, Graduate School of Engineering, Osaka Prefecture University, 1-1 Gakuen-cho, Naka-ku, Sakai, Osaka 599-8531
| | - Takeshi Maeda
- Department of Applied Chemistry, Graduate School of Engineering, Osaka Prefecture University, 1-1 Gakuen-cho, Naka-ku, Sakai, Osaka 599-8531
| | - Shigeyuki Yagi
- Department of Applied Chemistry, Graduate School of Engineering, Osaka Prefecture University, 1-1 Gakuen-cho, Naka-ku, Sakai, Osaka 599-8531
| |
Collapse
|
38
|
Ishigaki K, Ihara C, Mori-Yoshimura M, Murakami T, Sato T, Ishiguro K, Shichiji M, Nagata S, Kaiya H, Osawa M. Japanese nationwide registry for Fukuyama congenital muscular dystrophy patients. Neuromuscul Disord 2016. [DOI: 10.1016/j.nmd.2016.06.284] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
39
|
Ikeda H, Sasaki Y, Ishiguro K, Ishida T, Aoki Y, Tokino T. Abstract 3188: Targeted semiconductor sequencing of 409 cancer-related genes for somatic mutations and copy number variations in multiple myeloma. Cancer Res 2016. [DOI: 10.1158/1538-7445.am2016-3188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
2016's NCCN guideline recommended that induction therapy used conventional chemotherapy such as proteasome inhibitors and Imids in MM. Overall survival is improving by these Novel agents. However, we don't know how to choose these new agents. In the future, we can use next generation sequencer as a tool of drug choosing system. So we reviewed newly diagnosed 11 patients with MM who had received novel agents in our institution.The comprehensive analysis of genetic alterations in tumor by next generation sequencing can allow for the prediction of drug resistance and facilitate improvements in the treatment of MM patients.
Method:
DNA was extracted from magnetic bead-enriched bone marrow CD138-positive malignant plasma cells from 11 cases of MM, and CD138-negative cells were used as matched non-tumor cells. Forty nanograms of DNA were used for multiplex PCR amplification with an Ion Ampliseq Comprehensive Cancer Panel that offers targeted coverage of all exons in 409 tumor suppressor genes and oncogenes frequently cited and frequently mutated in human cancers. (covered regions: 95.4% of total). We sequenced 15,992 regions which obtained more than 1.5 megabases of target sequence.
Result:
Each sample underwent on average 8.3 million sequencing reads after quality filtering. The mean read depths were 539x, and >95% of targeted bases were represented by at least 20 reads. The average number of non-synonymous mutations detected per patient was 5.8 (range 0-11). We also detected copy number variations in which segments of the genome can be duplicated or deleted from sequencing data. We found several genetic alterations that may have been associated with the poor prognosis and poor response to chemotherapy of MM patients. Pathway assessment has shown that somatic aberrations within MM genomes are mainly involved in several important pathways, including cell cycle regulation, RTK-MAPK-PI3K and NF-kB.
Conclusion:
We performed targeted next-generation sequencing for rapid (2 days), standardized, and cost-effective gene analysis of malignant plasma cells from patients with MM. We can use targeted next-generation sequencing as tool of drug choosing system.
Citation Format: Hiroshi Ikeda, Yasushi Sasaki, Kazuya Ishiguro, Tadao Ishida, Yuka Aoki, Takashi Tokino. Targeted semiconductor sequencing of 409 cancer-related genes for somatic mutations and copy number variations in multiple myeloma. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3188.
Collapse
Affiliation(s)
| | | | | | | | - Yuka Aoki
- Sapporo Medical University, Sapporo, Japan
| | | |
Collapse
|
40
|
Igawa T, Hayashi T, Ishiguro K, Maruyama Y, Takeuchi M, Takata K, Yoshino T, Sato Y. IgG4-producing lymphoma arising in a patient with IgG4-related disease. Med Mol Morphol 2016; 49:243-249. [PMID: 27068526 DOI: 10.1007/s00795-016-0139-2] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2016] [Accepted: 03/31/2016] [Indexed: 12/24/2022]
Abstract
We herein report a case in which an IgG4-producing lymphoma arose in a patient with a previous diagnosis consistent with an IgG4-related disease. A 43-year-old man presented with enlarged cervical lymph nodes and was treated with steroids and radiation for what was initially assumed to be Kimura's disease, although the lesions were later histologically re-diagnosed as IgG4-related lymphadenopathy. Fourteen years later, when the patient was 58-years-old, he presented with retroperitoneal fibrosis and swollen lymph nodes. The suspicious lesions were not histologically examined as the patient did not give consent. However, the serum IgG4 concentration was high (1400 mg/dL) and he was clinically diagnosed with systemic IgG4-related disease. Although steroid administration reduced the size of the lesions, tapering the dose finally resulted in systemic, prominently enlarged lymph nodes. Analysis of the biopsy specimen revealed that these multiple lymph node lesions were marginal zone B cell lymphomas that themselves expressed IgG4. Complete remission was achieved after a total of six courses of chemotherapy including rituximab. This case suggests that the infiltrating IgG4-expressing cells observed in IgG4-related disease can clonally expand to malignant lymphomas.
Collapse
Affiliation(s)
- Takuro Igawa
- Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
| | - Toshiaki Hayashi
- Department of Gastroenterology, Rheumatology, and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Kazuya Ishiguro
- Department of Gastroenterology, Rheumatology, and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Yumiko Maruyama
- Department of Gastroenterology, Rheumatology, and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Mai Takeuchi
- Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
| | - Katsuyoshi Takata
- Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
| | - Tadashi Yoshino
- Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
| | - Yasuharu Sato
- Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
- Division of Pathophysiology, Okayama University Graduate School of Health Sciences, 2-5-1 Shikata-cho, Okayama, 700-8558, Japan.
| |
Collapse
|
41
|
Ishiguro K, Hayashi T, Aoki Y, Murakami R, Ikeda H, Ishida T. Other Iatrogenic Immunodeficiency-associated Lymphoproliferative Disorder Presenting as Primary Bone Lymphoma in a Patient with Rheumatoid Arthritis. Intern Med 2016; 55:2259-64. [PMID: 27523005 DOI: 10.2169/internalmedicine.55.6684] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Primary bone lymphoma (PBL) is a rare disorder. We herein present a case of other iatrogenic immunodeficiency-associated lymphoproliferative disorder (OIIA-LPD) presenting as PBL. A 63-year-old woman was diagnosed with rheumatoid arthritis and had been treated with methotrexate for seven years. Two months before admission, she suffered from pain in the limbs. Magnetic resonance imaging revealed multiple irregular lesions in the bones of the limbs, which showed an uptake of (18)F-FDG on positron emission tomography. A biopsy of the right radius revealed diffuse large B-cell lymphoma, leading to the diagnosis of OIIA-LPD. She received rituximab-containing regimens resulting in a complete response.
Collapse
Affiliation(s)
- Kazuya Ishiguro
- Department of Gastroenterology, Rheumatology, and Clinical Immunology, Sapporo Medical University School of Medicine, Japan
| | | | | | | | | | | |
Collapse
|
42
|
Ikeda H, Ishiguro K, Igarashi T, Aoki Y, Hayashi T, Ishida T, Sasaki Y, Tokino T, Shinomura Y. Molecular diagnostics of a single drug-resistant multiple myeloma case using targeted next-generation sequencing. Onco Targets Ther 2015; 8:2805-15. [PMID: 26491355 PMCID: PMC4599646 DOI: 10.2147/ott.s86515] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
A 69-year-old man was diagnosed with IgG λ-type multiple myeloma (MM), Stage II in October 2010. He was treated with one cycle of high-dose dexamethasone. After three cycles of bortezomib, the patient exhibited slow elevations in the free light-chain levels and developed a significant new increase of serum M protein. Bone marrow cytogenetic analysis revealed a complex karyotype characteristic of malignant plasma cells. To better understand the molecular pathogenesis of this patient, we sequenced for mutations in the entire coding regions of 409 cancer-related genes using a semiconductor-based sequencing platform. Sequencing analysis revealed eight nonsynonymous somatic mutations in addition to several copy number variants, including CCND1 and RB1. These alterations may play roles in the pathobiology of this disease. This targeted next-generation sequencing can allow for the prediction of drug resistance and facilitate improvements in the treatment of MM patients.
Collapse
Affiliation(s)
- Hiroshi Ikeda
- Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University, Sapporo, Japan
| | - Kazuya Ishiguro
- Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University, Sapporo, Japan
| | - Tetsuyuki Igarashi
- Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University, Sapporo, Japan
| | - Yuka Aoki
- Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University, Sapporo, Japan
| | - Toshiaki Hayashi
- Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University, Sapporo, Japan
| | - Tadao Ishida
- Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University, Sapporo, Japan
| | - Yasushi Sasaki
- Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University, Sapporo, Japan ; Medical Genome Sciences, Research Institute for Frontier Medicine, Sapporo Medical University, Sapporo, Japan
| | - Takashi Tokino
- Medical Genome Sciences, Research Institute for Frontier Medicine, Sapporo Medical University, Sapporo, Japan
| | - Yasuhisa Shinomura
- Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University, Sapporo, Japan
| |
Collapse
|
43
|
Murakami T, Uchiyama T, Nakayama T, Ishiguro K, Sato T, Kuru S, Ishigaki K. Assessment of growth and development in patients with Fukuyama congenital muscular dystrophy using bioelectrical impedance analysis. Neuromuscul Disord 2015. [DOI: 10.1016/j.nmd.2015.06.294] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
44
|
Shichiji M, Ishigaki K, Ishiguro K, Sato T, Murakami T, Muto A, Osawa M, Nagata S. Perinatal complications in patients with congenital myotonic dystrophy. Neuromuscul Disord 2015. [DOI: 10.1016/j.nmd.2015.06.100] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
45
|
Agafonova N, Aleksandrov A, Anokhina A, Aoki S, Ariga A, Ariga T, Bender D, Bertolin A, Bodnarchuk I, Bozza C, Brugnera R, Buonaura A, Buontempo S, Büttner B, Chernyavsky M, Chukanov A, Consiglio L, D'Ambrosio N, De Lellis G, De Serio M, Del Amo Sanchez P, Di Crescenzo A, Di Ferdinando D, Di Marco N, Dmitrievski S, Dracos M, Duchesneau D, Dusini S, Dzhatdoev T, Ebert J, Ereditato A, Fini RA, Fornari F, Fukuda T, Galati G, Garfagnini A, Goldberg J, Gornushkin Y, Grella G, Guler AM, Gustavino C, Hagner C, Hara T, Hayakawa H, Hollnagel A, Hosseini B, Ishiguro K, Jakovcic K, Jollet C, Kamiscioglu C, Kamiscioglu M, Kim JH, Kim SH, Kitagawa N, Klicek B, Kodama K, Komatsu M, Kose U, Kreslo I, Laudisio F, Lauria A, Ljubicic A, Longhin A, Loverre PF, Malgin A, Malenica M, Mandrioli G, Matsuo T, Matsushita T, Matveev V, Mauri N, Medinaceli E, Meregaglia A, Mikado S, Miyanishi M, Mizutani F, Monacelli P, Montesi MC, Morishima K, Muciaccia MT, Naganawa N, Naka T, Nakamura M, Nakano T, Nakatsuka Y, Niwa K, Ogawa S, Olchevsky A, Omura T, Ozaki K, Paoloni A, Paparella L, Park BD, Park IG, Pasqualini L, Pastore A, Patrizii L, Pessard H, Pistillo C, Podgrudkov D, Polukhina N, Pozzato M, Pupilli F, Roda M, Roganova T, Rokujo H, Rosa G, Ryazhskaya O, Sato O, Schembri A, Schmidt-Parzefall W, Shakirianova I, Shchedrina T, Sheshukov A, Shibuya H, Shiraishi T, Shoziyoev G, Simone S, Sioli M, Sirignano C, Sirri G, Sotnikov A, Spinetti M, Stanco L, Starkov N, Stellacci SM, Stipcevic M, Strolin P, Takahashi S, Tenti M, Terranova F, Tioukov V, Tufanli S, Vilain P, Vladymyrov M, Votano L, Vuilleumier JL, Wilquet G, Wonsak B, Yoon CS, Zemskova S. Discovery of τ Neutrino Appearance in the CNGS Neutrino Beam with the OPERA Experiment. Phys Rev Lett 2015; 115:121802. [PMID: 26430986 DOI: 10.1103/physrevlett.115.121802] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/07/2015] [Indexed: 06/05/2023]
Abstract
The OPERA experiment was designed to search for ν_{μ}→ν_{τ} oscillations in appearance mode, i.e., by detecting the τ leptons produced in charged current ν_{τ} interactions. The experiment took data from 2008 to 2012 in the CERN Neutrinos to Gran Sasso beam. The observation of the ν_{μ}→ν_{τ} appearance, achieved with four candidate events in a subsample of the data, was previously reported. In this Letter, a fifth ν_{τ} candidate event, found in an enlarged data sample, is described. Together with a further reduction of the expected background, the candidate events detected so far allow us to assess the discovery of ν_{μ}→ν_{τ} oscillations in appearance mode with a significance larger than 5σ.
Collapse
Affiliation(s)
- N Agafonova
- INR-Institute for Nuclear Research of the Russian Academy of Sciences, RUS-117312 Moscow, Russia
| | | | - A Anokhina
- SINP MSU-Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, RUS-119991 Moscow, Russia
| | - S Aoki
- Kobe University, J-657-8501 Kobe, Japan
| | - A Ariga
- Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), University of Bern, CH-3012 Bern, Switzerland
| | - T Ariga
- Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), University of Bern, CH-3012 Bern, Switzerland
| | - D Bender
- METU-Middle East Technical University, TR-06531 Ankara, Turkey
| | - A Bertolin
- INFN Sezione di Padova, I-35131 Padova, Italy
| | - I Bodnarchuk
- JINR-Joint Institute for Nuclear Research, RUS-141980 Dubna, Russia
| | - C Bozza
- Dipartimento di Fisica dell'Università di Salerno and "Gruppo Collegato" INFN, I-84084 Fisciano (Salerno), Italy
| | - R Brugnera
- INFN Sezione di Padova, I-35131 Padova, Italy
- Dipartimento di Fisica e Astronomia dell'Università di Padova, I-35131 Padova, Italy
| | - A Buonaura
- INFN Sezione di Napoli, 80125 Napoli, Italy
- Dipartimento di Fisica dell'Università Federico II di Napoli, I-80125 Napoli, Italy
| | | | - B Büttner
- Hamburg University, D-22761 Hamburg, Germany
| | - M Chernyavsky
- LPI-Lebedev Physical Institute of the Russian Academy of Sciences, RUS-119991 Moscow, Russia
| | - A Chukanov
- JINR-Joint Institute for Nuclear Research, RUS-141980 Dubna, Russia
| | | | - N D'Ambrosio
- INFN-Laboratori Nazionali del Gran Sasso, I-67010 Assergi (L'Aquila), Italy
| | - G De Lellis
- INFN Sezione di Napoli, 80125 Napoli, Italy
- Dipartimento di Fisica dell'Università Federico II di Napoli, I-80125 Napoli, Italy
| | - M De Serio
- Dipartimento di Fisica dell'Università di Bari, I-70126 Bari, Italy
- INFN Sezione di Bari, I-70126 Bari, Italy
| | - P Del Amo Sanchez
- LAPP, Université Savoie Mont Blanc, CNRS/IN2P3, F-74941 Annecy-le-Vieux, France
| | | | | | - N Di Marco
- INFN-Laboratori Nazionali del Gran Sasso, I-67010 Assergi (L'Aquila), Italy
| | - S Dmitrievski
- JINR-Joint Institute for Nuclear Research, RUS-141980 Dubna, Russia
| | - M Dracos
- IPHC, Université de Strasbourg, CNRS/IN2P3, F-67037 Strasbourg, France
| | - D Duchesneau
- LAPP, Université Savoie Mont Blanc, CNRS/IN2P3, F-74941 Annecy-le-Vieux, France
| | - S Dusini
- INFN Sezione di Padova, I-35131 Padova, Italy
| | - T Dzhatdoev
- SINP MSU-Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, RUS-119991 Moscow, Russia
| | - J Ebert
- Hamburg University, D-22761 Hamburg, Germany
| | - A Ereditato
- Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), University of Bern, CH-3012 Bern, Switzerland
| | - R A Fini
- INFN Sezione di Bari, I-70126 Bari, Italy
| | - F Fornari
- INFN Sezione di Bologna, I-40127 Bologna, Italy
- Dipartimento di Fisica e Astronomia dell'Università di Bologna, I-40127 Bologna, Italy
| | - T Fukuda
- Toho University, J-274-8510 Funabashi, Japan
| | - G Galati
- INFN Sezione di Napoli, 80125 Napoli, Italy
- Dipartimento di Fisica dell'Università Federico II di Napoli, I-80125 Napoli, Italy
| | - A Garfagnini
- INFN Sezione di Padova, I-35131 Padova, Italy
- Dipartimento di Fisica e Astronomia dell'Università di Padova, I-35131 Padova, Italy
| | - J Goldberg
- Department of Physics, Technion, IL-32000 Haifa, Israel
| | - Y Gornushkin
- JINR-Joint Institute for Nuclear Research, RUS-141980 Dubna, Russia
| | - G Grella
- Dipartimento di Fisica dell'Università di Salerno and "Gruppo Collegato" INFN, I-84084 Fisciano (Salerno), Italy
| | - A M Guler
- METU-Middle East Technical University, TR-06531 Ankara, Turkey
| | | | - C Hagner
- Hamburg University, D-22761 Hamburg, Germany
| | - T Hara
- Kobe University, J-657-8501 Kobe, Japan
| | - H Hayakawa
- Nagoya University, J-464-8602 Nagoya, Japan
| | - A Hollnagel
- Hamburg University, D-22761 Hamburg, Germany
| | - B Hosseini
- INFN Sezione di Napoli, 80125 Napoli, Italy
- Dipartimento di Fisica dell'Università Federico II di Napoli, I-80125 Napoli, Italy
| | - K Ishiguro
- Nagoya University, J-464-8602 Nagoya, Japan
| | - K Jakovcic
- IRB-Rudjer Boskovic Institute, HR-10002 Zagreb, Croatia
| | - C Jollet
- IPHC, Université de Strasbourg, CNRS/IN2P3, F-67037 Strasbourg, France
| | - C Kamiscioglu
- METU-Middle East Technical University, TR-06531 Ankara, Turkey
| | - M Kamiscioglu
- METU-Middle East Technical University, TR-06531 Ankara, Turkey
| | - J H Kim
- Gyeongsang National University, 900 Gazwa-dong, Jinju 660-701, Korea
| | - S H Kim
- Gyeongsang National University, 900 Gazwa-dong, Jinju 660-701, Korea
| | - N Kitagawa
- Nagoya University, J-464-8602 Nagoya, Japan
| | - B Klicek
- IRB-Rudjer Boskovic Institute, HR-10002 Zagreb, Croatia
| | - K Kodama
- Aichi University of Education, J-448-8542 Kariya (Aichi-Ken), Japan
| | - M Komatsu
- Nagoya University, J-464-8602 Nagoya, Japan
| | - U Kose
- INFN Sezione di Padova, I-35131 Padova, Italy
| | - I Kreslo
- Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), University of Bern, CH-3012 Bern, Switzerland
| | - F Laudisio
- Dipartimento di Fisica dell'Università di Salerno and "Gruppo Collegato" INFN, I-84084 Fisciano (Salerno), Italy
| | - A Lauria
- INFN Sezione di Napoli, 80125 Napoli, Italy
- Dipartimento di Fisica dell'Università Federico II di Napoli, I-80125 Napoli, Italy
| | - A Ljubicic
- IRB-Rudjer Boskovic Institute, HR-10002 Zagreb, Croatia
| | - A Longhin
- INFN-Laboratori Nazionali di Frascati dell'INFN, I-00044 Frascati (Roma), Italy
| | - P F Loverre
- INFN Sezione di Roma, I-00185 Roma, Italy
- Dipartimento di Fisica dell'Università di Roma "La Sapienza", I-00185 Roma, Italy
| | - A Malgin
- INR-Institute for Nuclear Research of the Russian Academy of Sciences, RUS-117312 Moscow, Russia
| | - M Malenica
- IRB-Rudjer Boskovic Institute, HR-10002 Zagreb, Croatia
| | - G Mandrioli
- INFN Sezione di Bologna, I-40127 Bologna, Italy
| | - T Matsuo
- Toho University, J-274-8510 Funabashi, Japan
| | | | - V Matveev
- INR-Institute for Nuclear Research of the Russian Academy of Sciences, RUS-117312 Moscow, Russia
| | - N Mauri
- INFN Sezione di Bologna, I-40127 Bologna, Italy
- Dipartimento di Fisica e Astronomia dell'Università di Bologna, I-40127 Bologna, Italy
| | - E Medinaceli
- INFN Sezione di Padova, I-35131 Padova, Italy
- Dipartimento di Fisica e Astronomia dell'Università di Padova, I-35131 Padova, Italy
| | - A Meregaglia
- IPHC, Université de Strasbourg, CNRS/IN2P3, F-67037 Strasbourg, France
| | - S Mikado
- Nihon University, J-275-8576 Narashino, Chiba, Japan
| | | | | | | | - M C Montesi
- INFN Sezione di Napoli, 80125 Napoli, Italy
- Dipartimento di Fisica dell'Università Federico II di Napoli, I-80125 Napoli, Italy
| | | | - M T Muciaccia
- Dipartimento di Fisica dell'Università di Bari, I-70126 Bari, Italy
- INFN Sezione di Bari, I-70126 Bari, Italy
| | - N Naganawa
- Nagoya University, J-464-8602 Nagoya, Japan
| | - T Naka
- Nagoya University, J-464-8602 Nagoya, Japan
| | - M Nakamura
- Nagoya University, J-464-8602 Nagoya, Japan
| | - T Nakano
- Nagoya University, J-464-8602 Nagoya, Japan
| | | | - K Niwa
- Nagoya University, J-464-8602 Nagoya, Japan
| | - S Ogawa
- Toho University, J-274-8510 Funabashi, Japan
| | - A Olchevsky
- JINR-Joint Institute for Nuclear Research, RUS-141980 Dubna, Russia
| | - T Omura
- Nagoya University, J-464-8602 Nagoya, Japan
| | - K Ozaki
- Kobe University, J-657-8501 Kobe, Japan
| | - A Paoloni
- INFN-Laboratori Nazionali di Frascati dell'INFN, I-00044 Frascati (Roma), Italy
| | - L Paparella
- Dipartimento di Fisica dell'Università di Bari, I-70126 Bari, Italy
- INFN Sezione di Bari, I-70126 Bari, Italy
| | - B D Park
- Gyeongsang National University, 900 Gazwa-dong, Jinju 660-701, Korea
| | - I G Park
- Gyeongsang National University, 900 Gazwa-dong, Jinju 660-701, Korea
| | - L Pasqualini
- INFN Sezione di Bologna, I-40127 Bologna, Italy
- Dipartimento di Fisica e Astronomia dell'Università di Bologna, I-40127 Bologna, Italy
| | - A Pastore
- Dipartimento di Fisica dell'Università di Bari, I-70126 Bari, Italy
| | - L Patrizii
- INFN Sezione di Bologna, I-40127 Bologna, Italy
| | - H Pessard
- LAPP, Université Savoie Mont Blanc, CNRS/IN2P3, F-74941 Annecy-le-Vieux, France
| | - C Pistillo
- Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), University of Bern, CH-3012 Bern, Switzerland
| | - D Podgrudkov
- SINP MSU-Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, RUS-119991 Moscow, Russia
| | - N Polukhina
- LPI-Lebedev Physical Institute of the Russian Academy of Sciences, RUS-119991 Moscow, Russia
| | - M Pozzato
- INFN Sezione di Bologna, I-40127 Bologna, Italy
- Dipartimento di Fisica e Astronomia dell'Università di Bologna, I-40127 Bologna, Italy
| | - F Pupilli
- INFN-Laboratori Nazionali di Frascati dell'INFN, I-00044 Frascati (Roma), Italy
| | - M Roda
- INFN Sezione di Padova, I-35131 Padova, Italy
- Dipartimento di Fisica e Astronomia dell'Università di Padova, I-35131 Padova, Italy
| | - T Roganova
- SINP MSU-Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, RUS-119991 Moscow, Russia
| | - H Rokujo
- Nagoya University, J-464-8602 Nagoya, Japan
| | - G Rosa
- INFN Sezione di Roma, I-00185 Roma, Italy
- Dipartimento di Fisica dell'Università di Roma "La Sapienza", I-00185 Roma, Italy
| | - O Ryazhskaya
- INR-Institute for Nuclear Research of the Russian Academy of Sciences, RUS-117312 Moscow, Russia
| | - O Sato
- Nagoya University, J-464-8602 Nagoya, Japan
| | - A Schembri
- INFN-Laboratori Nazionali del Gran Sasso, I-67010 Assergi (L'Aquila), Italy
| | | | - I Shakirianova
- INR-Institute for Nuclear Research of the Russian Academy of Sciences, RUS-117312 Moscow, Russia
| | - T Shchedrina
- Dipartimento di Fisica dell'Università Federico II di Napoli, I-80125 Napoli, Italy
- LPI-Lebedev Physical Institute of the Russian Academy of Sciences, RUS-119991 Moscow, Russia
| | - A Sheshukov
- JINR-Joint Institute for Nuclear Research, RUS-141980 Dubna, Russia
| | - H Shibuya
- Toho University, J-274-8510 Funabashi, Japan
| | | | - G Shoziyoev
- SINP MSU-Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, RUS-119991 Moscow, Russia
| | - S Simone
- Dipartimento di Fisica dell'Università di Bari, I-70126 Bari, Italy
- INFN Sezione di Bari, I-70126 Bari, Italy
| | - M Sioli
- INFN Sezione di Bologna, I-40127 Bologna, Italy
- Dipartimento di Fisica e Astronomia dell'Università di Bologna, I-40127 Bologna, Italy
| | - C Sirignano
- INFN Sezione di Padova, I-35131 Padova, Italy
- Dipartimento di Fisica e Astronomia dell'Università di Padova, I-35131 Padova, Italy
| | - G Sirri
- INFN Sezione di Bologna, I-40127 Bologna, Italy
| | - A Sotnikov
- JINR-Joint Institute for Nuclear Research, RUS-141980 Dubna, Russia
| | - M Spinetti
- INFN-Laboratori Nazionali di Frascati dell'INFN, I-00044 Frascati (Roma), Italy
| | - L Stanco
- INFN Sezione di Padova, I-35131 Padova, Italy
| | - N Starkov
- LPI-Lebedev Physical Institute of the Russian Academy of Sciences, RUS-119991 Moscow, Russia
| | - S M Stellacci
- Dipartimento di Fisica dell'Università di Salerno and "Gruppo Collegato" INFN, I-84084 Fisciano (Salerno), Italy
| | - M Stipcevic
- IRB-Rudjer Boskovic Institute, HR-10002 Zagreb, Croatia
| | - P Strolin
- INFN Sezione di Napoli, 80125 Napoli, Italy
- Dipartimento di Fisica dell'Università Federico II di Napoli, I-80125 Napoli, Italy
| | | | - M Tenti
- INFN Sezione di Bologna, I-40127 Bologna, Italy
| | - F Terranova
- INFN-Laboratori Nazionali di Frascati dell'INFN, I-00044 Frascati (Roma), Italy
- Dipartimento di Fisica dell'Università di Milano-Bicocca, I-20126 Milano, Italy
| | - V Tioukov
- INFN Sezione di Napoli, 80125 Napoli, Italy
| | - S Tufanli
- Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), University of Bern, CH-3012 Bern, Switzerland
| | - P Vilain
- IIHE, Université Libre de Bruxelles, B-1050 Brussels, Belgium
| | - M Vladymyrov
- LPI-Lebedev Physical Institute of the Russian Academy of Sciences, RUS-119991 Moscow, Russia
| | - L Votano
- INFN-Laboratori Nazionali di Frascati dell'INFN, I-00044 Frascati (Roma), Italy
| | - J L Vuilleumier
- Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), University of Bern, CH-3012 Bern, Switzerland
| | - G Wilquet
- IIHE, Université Libre de Bruxelles, B-1050 Brussels, Belgium
| | - B Wonsak
- Hamburg University, D-22761 Hamburg, Germany
| | - C S Yoon
- Gyeongsang National University, 900 Gazwa-dong, Jinju 660-701, Korea
| | - S Zemskova
- JINR-Joint Institute for Nuclear Research, RUS-141980 Dubna, Russia
| |
Collapse
|
46
|
Ishiguro K, Hayashi T, Igarashi T, Maruyama Y, Ikeda H, Ishida T, Shinomura Y. Decrease of B-type natriuretic peptide to less than 200 pg/mL predicts longer survival in cardiac immunoglobulin light chain amyloidosis. Int J Hematol 2015; 102:200-4. [DOI: 10.1007/s12185-015-1814-0] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2015] [Revised: 05/14/2015] [Accepted: 05/15/2015] [Indexed: 10/23/2022]
|
47
|
Ishiguro K, Lin Z, Rutherford T, Ratner E. Antitumor activity of the ribonucleotide reductase inhibitor Triapine alone or in combination with paclitaxel. Gynecol Oncol 2015. [DOI: 10.1016/j.ygyno.2015.01.193] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
48
|
Ishiguro K, Ishigaki K, Sato T, Murakami T, Saito K, Osawa M, Nagata S. G.P.318. Neuromuscul Disord 2014. [DOI: 10.1016/j.nmd.2014.06.408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
49
|
|
50
|
Ishiguro K, Hayashi T, Aoki Y, Maruyama Y, Ikeda H, Ishida T, Shinomura Y. [Allogeneic bone marrow transplantation in a patient with primary hepatic diffuse large B-cell lymphoma that relapsed after autologous stem cell transplantation]. Nihon Shokakibyo Gakkai Zasshi 2014; 111:1798-1804. [PMID: 25195965] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
A 64-year-old woman was admitted to our hospital due to a relapse of primary hepatic lymphoma (PHL). Three years previously, she had been referred to our hospital with a history of chronic hepatitis B for further examination of severe liver dysfunction, at which point a liver biopsy revealed PHL. She received conventional chemotherapy resulting in complete response (CR). An autologous stem cell transplantation was subsequently performed. However, 25 months after the transplantation, she suffered a relapse of PHL and was readmitted to our hospital. She achieved CR after treatment with salvage chemotherapy and then received an allogeneic bone marrow transplantation. CR has since been maintained for more than one year. This case provides insight about treatment choices in PHL.
Collapse
Affiliation(s)
- Kazuya Ishiguro
- Department of Gastroenterology, Rheumatology, and Clinical Immunology, Sapporo Medical University School of Medicine
| | | | | | | | | | | | | |
Collapse
|